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Background: In Cameroon, HIV infections range between 550, 000 to 690, 000 for 
adults aged 15 to 49 years and a prevalence rate at 4.5%. In children of 0 – 14 years, 
HIV infections range between 34, 000 to 44, 000. The country harbors both HIV type 
1 (HIV-1) and HIV type 2 (HIV-2). HIV groups found in Cameroon include M, N, O, P 
variants. Group M subtypes are the most prevalent, with CRF02_AG accounting for 
approximately 40% of all HIV infections. This is unlike other regions globally where 
other group M subtypes like C are the predominant ones. The high genomic diversity 
of HIV-1 and the emergence of drug resistant associated mutations (RAMs) continue 
to be a major challenge in designing standardized laboratory protocols for HIV 
testing, vaccine development and providing successful lifelong therapy to HIV 
infected patients. In Cameroon, drug resistance rates for therapy naïve individuals 
are currently at 3.8% in adults and 3.6% in children. This study aimed at identifying 
HIV-1 diversity and evaluate drug resistant mutations (DRMs) in two different cohorts 
of therapy-naïve infants/children and adults in Cameroon. Methods: A total of 180 
plasma samples were collected from therapy naïve HIV positive patients that 
included: (1) 55 plasma samples from proxy-consented infants/children aged 9-72 
months old with unknown prevention of mother-to-child transmission (PMTCT) 
exposure and (2) 125 plasma samples from adults of 15 to 50 years old. The CD4+ 
T-cell count was performed using standard methods following manufacturer’s 
instructions. To study the HIV-1 diversity and resistance in the two cohorts, partial pol 
Protease (PR), Reverse Transcriptase (RT) and Integrase (IN) regions of the HIV-1 
genome were targeted for conventional PCR amplification and Sanger DNA 





sequencing. Phylogenetic inference using Neighbor-Joining (NJ) trees were used to 
cluster and infer subtypes. Results: In the infants/children cohort, the CD4+ T-cell 
count ranged between 500-2000 cells/m3 (a median of 33.0%) and the HIV-1 viral 
load between 3000-6000 copies/ml (a median of 4.96 RNA copies/ml). A total of 
37/55 (67.3%) paediatric cohort samples were amplified for at least one of the HIV-1 
pol fragments. These include 29/55 (52.0%) for the PR, 27/55 (49.0%) for the RT and 
28/55 (51.0%) for IN. The most predominant HIV-1 strain was G/CRF02_AG at 
62.5% (n = 15). Other subtypes detected include subtype A (20.8%; n = 5), C (8.3%; 
n = 2) and F2 (8.3%; n = 2). Three sequences (11.1%) could not be assigned to any 
subtype with confidence. Levels of DRMs to Protease inhibitors (PIs), nucleoside 
reverse transcriptase inhibitors (NRTIs) and non-NRTI were 27.6% (only minor 
DRMS were observed for PR), 3.7% and 40.7%, respectively. The NRTI mutations 
observed showed high-level resistance to Zidovudine (AZT), Tenofovir (TDF), 
Didanosine (DDI) and Stavudine (D4T), and low to intermediate-level resistance to 
Lamivudine (3TC), Abacavir (ABC), and Emtricitabine (FTC). The NNRTI mutations 
observed showed high level resistance to Nevirapine (NVP) and Efavirenz (EFV) with 
reduced susceptibility to Etravirine (ETR) and Rilpivirine (RPV). In the adult cohort, 
the RT fragment (n = 55) was used for phylogenetic analysis with majority of the 
sample sequences clustered with HIV-1 subtype G/CRF02_AG which accounted for 
40% (n = 22), CRF22_01A1 (10.9%; n = 6), C (1.8%; n = 1), B (1.8%; n = 1), other 
complex forms – 37_cpx/11_cpx (3.6%; n = 2). Twenty three samples (41.8%) could 
not be assigned to any subtype with confidence. The levels of drug resistance for 
adults was 5.4% for both NRT and NNRT inhibitors - 4.0% had low level resistance to 
EFV, ETR, NVP and RPV while 1.4% had intermediate to high level resistance to 





ABC, FTC, TDF, EFV and NVP. Conclusion: Cameroon continues to harbor many 
HIV-1 subtypes and circulating recombinant forms (CRFs) as observed in both 
cohorts. Furthermore, rare group O and other group M subtypes like C were noticed 
within the study cohorts suggesting an improvement in sensitivity of detection 
methodologies currently used. Drug resistance is a major challenge to current 
antiretroviral drug regimens as illustrated by the detection of RAMS in both cohorts of 
this study. Continuous surveillance of the HIV diversity and drug resistance is 
therefore necessary to better manage the HIV-1 pandemic. 
  






I most sincerely thank my supervisor Dr. Graeme Brendon Jacobs for believing in me 
and giving me a chance to pursue this course under his supervision. You have 
nurtured me with a wide range of skills in the realm of scientific research that forever 
will be engrained in my memory. My gratitude also goes to my co-supervisor Dr. 
George Mondinde Ikomey and your team at CSCCD in Cameroon, you made it 
possible for me to access the samples and your input in various stages of my project 
cannot be taken for granted. I thank you all (Merci!). Professor Susan Engelbrecht, 
nothing can describe you better than the knowledge in phylogenetic analyses that 
largely I gained from you, with much appreciation. Thank you Professor Wolfgang 
Preiser and Professor Andrew Whitelaw, you made it possible for me to register late - 
giving me an opportunity that I had thought was long gone. I salute you! Professor 
Loice Gathece and Dr. EAO Dimba - I deeply appreciate every effort you made for 
me to join this program. Mr. Njenda Duncan (our research assistant), Ms. Cynthia 
Tamandjou, Ms. Poovan and Comrades - Mr. Given Mikasi, Mr. Emmanuel Obasa, 
Mr. Ruhanya and Dr. Laundry - your help, suggestions and positive criticisms in my 
laboratory work and thesis writing made my project a success. Thank you all. Mrs. 
Sal van Zyl (our division secretary), Mrs. Rachel Pullen (international office), Mrs. Du 
Plessis Nina, fellow students and other staff in the Division and National Health 
Laboratory Services (NHLS) -  thank you for supporting me and working with me. Dr. 
David Otieno Awange, Dr. Wakoli and Mrs. Alice Limo - you took my duties in our 
pathology laboratory section while I was away and supported me in many different 
ways. Thank you. Finally, the P4HPT (intra-acp), University of Nairobi and 





Stellenbosch University management - thank you for the financial support and the 
opportunity to study. 
  






To my dear wife Gladys Kerubo, our two beautiful daughters - Marion Moraa and 
Faith Meroka and our son, Emmanuel Gichana, I dedicate this to you all for your 
unwavering support and understanding. It was not easy being far away from you for 
two and half years but your love gave me a reason to be strong and courageous in all 
I do. Forever God bless you. 
To my dear parents – Mr. Solomon Gichana and Mrs. Jemimah Meroka - God bless 
you for all you have done for me. The virtues you instilled in me, is what has made 
me to be who I am today. My dear brothers and sisters- your love, financial support, 
words of hope and encouragement endeavored the smooth running of my career. 
God bless you all. 
  





Table of contents 
DECLARATION ............................................................................................................................... I 
ABSTRACT .................................................................................................................................... II 
ACKNOWLEDGMENTS ................................................................................................................... V 
DEDICATIONS ............................................................................................................................. VII 
TABLE OF CONTENTS ................................................................................................................. VIII 
WORK SUBMITTED FOR PUBLICATION ....................................................................................... XIV 
CONFERENCES AND WORKSHOP ATTENDED ............................................................................... XIV 
LIST OF ABBREVIATION .............................................................................................................. XVI 
LIST OF TABLES ......................................................................................................................... XXV 
LIST OF FIGURES ..................................................................................................................... XXVII 
CHAPTER 1 INTRODUCTION AND LITERATURE REVIEW........................................................... 29 
 INTRODUCTION ............................................................................................................................ 31 
 LITERATURE REVIEW ..................................................................................................................... 33 
1.2.1 Origin of HIV ..................................................................................................................... 33 
1.2.2 HIV diversity ...................................................................................................................... 34 
1.2.3 HIV infections in Humans ................................................................................................. 36 
1.2.4 HIV global distribution ...................................................................................................... 38 
1.2.5 HIV-1 structure and genomic organization ...................................................................... 39 
1.2.6 HIV-1 Replication cycle ..................................................................................................... 45 
1.2.7 HIV-1 immunopathogenesis ............................................................................................. 49 
1.2.8 Natural resistance ............................................................................................................ 50 





1.2.9 HIV-1 treatment ................................................................................................................ 52 
1.2.10 Mechanism of cART action ............................................................................................. 55 
1.2.11 HIV drug resistance (HIVDR) ........................................................................................... 57 
1.2.12 Drug resistance testing ................................................................................................... 59 
1.2.13 HIV infection in Cameroon .............................................................................................. 60 
1.2.14 Aim and specific objective of the study .......................................................................... 62 
CHAPTER 2 MATERIAL AND METHODS................................................................................... 64 
 INTRODUCTION ............................................................................................................................ 66 
 ETHICAL STATEMENT ..................................................................................................................... 66 
 STUDY DESIGN............................................................................................................................. 67 
 STUDY PARTICIPANTS .................................................................................................................... 68 
 EQUIPMENT, CHEMICALS, REAGENTS, COMMERCIAL ASSAYS AND ENZYMES ............................................ 69 
 SAMPLE COLLECTION, PREPARATION AND STORAGE ............................................................................ 72 
 HIV TESTING ............................................................................................................................... 73 
 DETERMINATION OF CLUSTER OF DIFFERENTIATION 4 THYMUS-CELL COUNTS AND PERCENTAGES .............. 73 
 RNA EXTRACTION ........................................................................................................................ 75 
 VIRAL LOAD SCREENING .............................................................................................................. 76 
 RNA CONCENTRATION AND QUALITY ESTIMATION ........................................................................... 76 
 LOCATION OF GENOME OF INTEREST ............................................................................................. 77 
 PRIMERS FOR PCR AMPLIFICATION ............................................................................................... 77 
 POLYMERASE CHAIN REACTION .................................................................................................... 79 
2.14.1 Pre-nested RT- PCR ......................................................................................................... 80 
2.14.2 Nested PCR ..................................................................................................................... 82 
2.14.3 Visualization of the nested PCR amplicons ..................................................................... 83 





2.14.4 Purification of PCR products ........................................................................................... 84 
 DNA SEQUENCING ..................................................................................................................... 85 
2.15.1 Quality control of DNA sequences .................................................................................. 87 
2.15.2 Multiple sequence alignment ......................................................................................... 87 
 HIV-1 SUBTYPING USING ONLINE PROGRAMS ................................................................................. 88 
 DRUG RESISTANCE ANALYSES ....................................................................................................... 88 
 PHYLOGENETIC INFERENCE .......................................................................................................... 89 
CHAPTER 3 RESULTS – COHORT I ........................................................................................... 91 
 SOCIAL-DEMOGRAPHICS AND CLINICAL DATA .................................................................................... 92 
 VIRAL RNA AMPLICONS ................................................................................................................ 93 
 DETECTION OF PCR AMPLICONS (PR, RT AND IN) ............................................................................. 94 
 SEQUENCING ............................................................................................................................... 96 
 SEQUENCE ALIGNMENT ................................................................................................................. 97 
 PRELIMINARY HIV-1 SUBTYPING USING VARIOUS ONLINE PROGRAMMES ............................................... 99 
3.6.1 Jumping profile Hidden Markov Model (jpHMM) ............................................................ 99 
3.6.2 Recombinant Identification Program (RIP) ..................................................................... 100 
3.6.3 REGA version 3.0 ............................................................................................................ 101 
3.6.4 SCUEAL (DataMonkey Program) .................................................................................... 102 
3.6.5 Context-based Modeling for Expeditious Typing Program (COMET) ............................. 102 
3.6.6 Stanford University HIV Drug Resistance Database ....................................................... 103 
 GROUP O SAMPLE ...................................................................................................................... 107 
 PHYLOGENETIC ANALYSES ............................................................................................................ 109 
 HIV-1 DRUG RESISTANCE ASSOCIATED MUTATIONS IN THE POL (PR, RT AND IN) GENOME ..................... 114 
3.9.1 Protease RAMs ............................................................................................................... 114 





3.9.2 NRTIs and NNRTIs RAMs ................................................................................................. 117 
3.9.3 Integrase RAMS .............................................................................................................. 120 
CHAPTER 4 DISCUSSION ...................................................................................................... 122 
 OVERVIEW OF THE STUDY ............................................................................................................ 123 
 HIV DIVERSITY ........................................................................................................................... 124 
 OBSERVED HIV SUBTYPES USING VARIOUS ONLINE SUBTYPING PROGRAMS .......................................... 124 
 NEIGHBOR – JOINING PHYLOGENETIC INFERENCE ............................................................................. 126 
4.4.1 Group O sequence .......................................................................................................... 127 
 HIV-1 IMMUNOLOGIC AND VIROLOGICAL MARKERS ......................................................................... 128 
 CART FOR INFANTS/CHILDREN IN CAMEROON ................................................................................ 129 
 RESISTANCE ASSOCIATED MUTATIONS AND POLYMORPHISMS IN CAMEROON ....................................... 130 
4.7.1 Protease mutations ........................................................................................................ 130 
4.7.2 Reverse transcriptase mutations .................................................................................... 131 
4.7.3 Integrase mutations ....................................................................................................... 132 
 IMPACT OF THIS STUDY COHORT IN HIV MANAGEMENT .................................................................... 133 
CHAPTER 5 MATERIALS AND METHODS – COHORT II ........................................................... 134 
 INTRODUCTION .......................................................................................................................... 135 
 ETHICAL STATEMENT ................................................................................................................... 135 
 STUDY DESIGN ........................................................................................................................... 135 
 STUDY PARTICIPANTS .................................................................................................................. 135 
 EQUIPMENT, CHEMICALS, REAGENTS, COMMERCIAL ASSAYS AND ENZYMES .......................................... 135 
 SAMPLE COLLECTION, PREPARATION AND STORAGE .......................................................................... 136 
 VIRAL RNA EXTRACTION ............................................................................................................. 136 
 VIRAL RNA CONCENTRATION AND ESTIMATION ............................................................................... 136 





 LOCATION OF GENOME OF INTEREST (POL GENOME) ........................................................................ 136 
 PCR AMPLIFICATION ................................................................................................................ 136 
 DETECTION AND PURIFICATION OF PCR AMPLICONS (PR AND RT) ................................................... 137 
 SEQUENCING ........................................................................................................................... 137 
 QUALITY CONTROL ................................................................................................................... 137 
 ALIGNMENT ............................................................................................................................ 138 
 PRELIMINARY HIV-1 SUBTYPING USING ONLINE PROGRAMS ............................................................ 138 
 PHYLOGENETIC INFERENCE ........................................................................................................ 138 
 DRUG RESISTANCE ANALYSES ..................................................................................................... 138 
CHAPTER 6 RESULTS - COHORT II ......................................................................................... 139 
 POSITIVELY AMPLIFIED POL GENE (PR AND RT) FRAGMENTS .............................................................. 140 
 SEQUENCING AND ALIGNMENT ..................................................................................................... 142 
 PRELIMINARY HIV-1 SUBTYPING USING VARIOUS ONLINE PROGRAMS ................................................. 143 
6.3.1 REGA subtyping program ............................................................................................... 149 
6.3.2 jumping profile Hidden Markov Model (jpHMM) ........................................................... 150 
6.3.3 Recombinant Identification Program (RIP) ..................................................................... 151 
6.3.4 SCUEAL (DataMonkey program) .................................................................................... 152 
6.3.5 Context-based Modeling for Expeditious Typing (COMET) ............................................ 152 
6.3.6 Stanford HIV drug database Subtyping programme ...................................................... 153 
6.3.7 Phylogenetic analysis ..................................................................................................... 153 
6.3.8 HIV-1 resistance associated mutations in the pol gene (PR and RT) .............................. 155 
CHAPTER 7 DISCUSSION – COHORT II ................................................................................... 156 
 OVERVIEW OF COHORT II STUDY ................................................................................................... 157 
 OBSERVED HIV DIVERSITY ........................................................................................................... 157 





 OBSERVED DRUG RESISTANCE ASSOCIATED MUTATIONS .................................................................... 159 
CHAPTER 8 GENERAL DISCUSSION AND CONCLUSION .......................................................... 161 
 GENERAL DISCUSSION ................................................................................................................. 162 
 LIMITATIONS ............................................................................................................................. 165 
 CONCLUSION ............................................................................................................................. 165 
 FUTURE RESEARCH INVESTIGATIONS .............................................................................................. 166 
REFERENCES ............................................................................................................................. 168 
APPENDIX I .............................................................................................................................. 190 
APPENDIX II ............................................................................................................................. 192 
APPENDIX III ............................................................................................................................ 193 
  





Work submitted for publication 
Ikomey G.M., Assoumou O., Gichana J.O., Njenda D., Mikasi S.G., Mesembe M., 
Lyonga E., Jacobs G.B.: Observed HIV drug resistance associated mutations 
amongst naïve immunocompetent children in Yaoundé, Cameroon; Ref: GERMS-
OA-2017-0019.R1. Accepted, in press. 2017.  
Manuscript for submission 
Gichana J.O., Ikomey G.M, Mesembe M., Lyonga E., Jacobs G.B.: HIV-1 Pol-
Phylogenetic diversity and drug resistance mutation profile in adults from Yaounde 
,Cameroon – to be submitted to GERMS in October, 2017. 
Conferences and workshop attended 
17th – 21st July, 2017. International Union of Microbiological Societies (IUMS) 2017 
Congresses - 17th International Congress of Virology, Singapore. Poster 
presentation: HIV-1 Pol-phylogenetic diversity and drug resistance mutation profile in 
two different cohorts (adult and infants) from Yaoundé, Cameroon: Gichana J.O., 
Ikomey G.M., and Jacobs G.B. 
19th - 23rd June, 2017. Introduction to phylogenetics and Advanced phylogenetics 
workshop 
24th May, 2016. American Society of Microbiology (ASM) at Centre for the Study 
and Control of Communicable Diseases Institute, Yaoundé Cameroon. Oral 





presentation:  HIV-1 diversity and resistance in a cohort of infants from Yaoundé, 
Cameroon. 
1st – 3rd December, 2015. Virology Africa 2015 conference in Cape Town, South 
Africa. Poster presentation: HIV-1 diversity and resistance in a cohort of infants from 
Yaoundé, Cameroon:  Gichana J.O., George Ikomey G.M., Njenda D., Graeme B. J.  
  





List of Abbreviation 
3TC:   Lamivudine 
AIDS:   Acquired immunodeficiency syndrome 
ART:   Antiretroviral therapy 
ARV drugs:  Antiretroviral drugs 
aa:   Amino acid 
APOBEC3G:  Apolipoprotein B mRNA-editing enzyme-catalytic Polypeptide- 
                                 like 3G 
ABC:   Abacavir 
ATV/r:   Atazanavir/ritonavir 
AZT:   Zidovudine 
BLAST:  Basic Local Alignment Search Tool 
Bp:   Base pairs 
Bpi:   Boosted protease inhibitors 
C1 to C5:  Constant regions 1 to 5 
CA:   Capsid 
cART:   Combination antiretroviral therapy 





CD:   Cluster of differentiation (CD3, CD4, CD8) 
cDNA:   Complementary deoxynucleic acid 
CCR5:  C-C chemokine receptor type 5 
CM:   Cameroon (samples) 
CRFs:   Circulating recombinant forms 
COMET:  Context-based Modeling for Expeditious Typing 
CTLs:   Cytotoxic T-lymphocytes 
CXCR4:  C-X-C chemokine receptor type 4 
d4T:   Stavudine 
dNTPs:  Deoxynucleoside triphosphates 
ddNTPs:  Dideoxynucleoside triphosphates 
ddNTPs - A,G,C,T: Adenosine, Guanine, Cytosine, Thymine 
DC:   Dendritic Cells 
ddI:   Didanosine 
DNA:   Deoxyribonucleic acid 
DRV:   Darunavir 
DRC:   Democratic Republic of Congo 





DTG:   Dolutegravir 
EDTA:  Ethylene diamine tetra-acetic acid 
EFV:   Efavirenz 
Env :   Envelope gene 
Env :   Envelope protein 
ER:   Endoplasmic reticulum 
ETR:   Etravirine   
EVG:   Elvitegravir 
FACS:  Fluorescent Assorted Cells Sorter 
FSW:   Female sex worker 
FTC:   Emtricitabine 
GACB :  Germany Advisory Committee Blood 
gag:   Group-specific antigen gene 
gp:   Glycoprotein 
GTR:   General time reversible 
HHV8:  Human herpes virus 8 
HIV:   Human Immunodeficiency Virus 





HIV-1:   Human Immunodeficiency Virus type 1 
HIV-2:   Human Immunodeficiency Virus type 2 
HIVDB:  HIV drug resistance database 
HIVDR:  HIV drug resistance 
HLA:   Human Leukocyte Antigen 
HREC:  Human Research Ethics Committee 
HTLV:   Human T-Lymphotropic virus 
IDV/r:   Indinavir/r 
IDUs:   Intravenous drugs users 
IN:   Integrase 
INIs:   Integrase inhibitors 
jpHMM:  jumping profile Hidden Markov Model 
kDa:   kilo Dalton 
kb:   Kilo – base pairs 
LAS:   Lymphadenopathy syndrome 
LAV:   Lymphadenopathy virus 
LANL:   Los Alamos National Laboratory 





LTNPs:  Long–term non-progressors 
LPV/r:   Lopinavir/ritonavir 
LTR:   Long terminal repeat 
MA:   Matrix protein 
MEGA:  Molecular evolutionary genetics analysis 
MHC:   Major Histocompatibility Complex 
mRNA:  Messenger Ribonucleic acid  
MSM:   Men having sex with men 
MTCT :  Mother-to-child transmission 
NC:   Nucleocapsid 
nef:   Negative factor gene 
NF – kβ:  Nuclear factor kβ 
NFV:   Nelfinavir 
NNRTIs:  Non-nucleoside/nucleotide reverse transcriptase inhibitors 
NRTIs:  Nucleoside/Nucleotide reverse transcriptase inhibitors 
NTC:   Non-Template Control 
NTD:   N-terminal domain 





NVP:   Nevirapine 
ORF:   Open reading frame 
PBS buffer:  Phosphate buffer saline buffer 
PBS:   Primer binding site    
PC:   Positive Control 
PCR:   Polymerase chain reaction 
PI:   Protease inhibitor 
PIC:   Pre- Integration complex 
PLHA:   People living with HIV/AIDS 
PMTCT:  Prevention of mother-to-child transmission 
PR:   Protease 
Pol:   Polymerase gene 
®:   Registered 
R:   Ritonavir 
RAMs:  Resistance associated mutations 
rev:   Regulator of viral expression gene 
RIP:   Recombinant Identification Program 





RNA:   Ribonucleic acid 
rpm:   Revolution per minute 
RPV:   Rilpivirine 
RTV:   Ritonavir 
RT:   Reverse transcriptase 
RTIs:   Reverse transcriptase inhibitors 
SCUEAL:  Subtype classification using evolutionary algorithms 
SDRM:  Surveillance drug resistant mutations 
SHAPE:  Selective 2’-hydroxyl acylation analyzed by primer extension  
SIV:   Simian immunodeficiency virus 
SIVcpz:  SIVs of chimpanzee 
SIVgor:  SIVs of Gorilla 
SIVsm:  SIVs of sooty mangabeys 
SU:   Surface glycoproteins 
TAMs:   Thymidine analogue mutations 
tat:   Trans-activator of transcription gene 
Taq:   Thermus aquaticus 





TDF:   Tenofovir 
tHIVDR:  Transmitted HIV drug resistance  
TM:   Transmembrane 
TPV/r:   Tipranavir/ritonavir 
TRIM:   Tripartite motif  
TAE:   Tris-Acetate-EDTA 
UNAIDS:  Joint United Nations programme on HIV/AIDS 
URFs:   Unique recombinant forms 
U3:   Unique 3’ region 
U5:   Unique 5’ region 
USA:   United States of America 
US-FDA:  United States Food and Drug Administrations 
V1 to V5:  Variable regions 1 to 5 
V3:   Third Variable 
Vif:   Virion infectivity factor gene 
Vpr:   Viral protein R gene 
vpu:    Viral protein U gene 





WHO:   World Health Organization 
  





List of tables 
Table 1.1 FDA approved classes of drugs and date of approval ...................................................................... 53 
Table 2.1 Equipment used for sample assays and analysis ............................................................................. 69 
Table 2.2 Chemical reagents, commercial assay kits and enzymes ................................................................. 70 
Table 2.3 Software packages .......................................................................................................................... 71 
Table 2.4 Databases used for sequence analysis ............................................................................................ 71 
Table 2.5 Miscellaneous items ....................................................................................................................... 72 
Table 2.6 PR Fragment amplification primers ................................................................................................. 78 
Table 2.7 RT fragment amplification primers ................................................................................................. 78 
Table 2.8 IN fragment amplification primers .................................................................................................. 79 
Table 2.9 A master mix for pre-nested PCR in a 50 µL reaction volume reaction ............................................ 81 
Table 2.10 Cycling conditions for Pre-nested PCR ........................................................................................... 81 
Table 2.11 A master mix for Nested PCR (PR fragment) in a 50 reaction volume ............................................ 82 
Table 2.12 Cycling conditions for nested PCR ................................................................................................. 83 
Table 2.13 Sequencing primers ...................................................................................................................... 86 
Table 2.14 Sequence PCR cycling parameters ................................................................................................. 87 
Table 3.1 Summary of infants/children clinical and demographic data .......................................................... 93 
Table 3.2 Summary of positively amplified pol gene fragments ..................................................................... 96 
Table 3.3 Summary of HIV-1 subtype analyses based on pol (PR) fragment using six different online 
programmes ........................................................................................................................................ 103 
Table 3.4 Summary of HIV-1 subtype analyses based on pol (RT) fragment using six different online 
programmes ........................................................................................................................................ 104 
Table 3.5 Summary of HIV-1 subtype analyses based on pol (IN) fragment using five different online 
programmes. ....................................................................................................................................... 106 
Table 3.6 Minor PI RAMs as observed in the PR region of the HIV-1 genome using Stanford HIV Drug 
Resistance database ............................................................................................................................ 115 





Table 3.7 Resistance Associated Mutations against RT genomic region using Stanford HIV Drug Resistance 
database ............................................................................................................................................. 117 
Table 6.1 Summary of positively amplified pol gene fragments (n = 125) ..................................................... 140 
Table 6.2 PR Fragment for Cohort II ............................................................................................................. 144 
Table 6.3 RT Fragment for Cohort II .............................................................................................................. 147 
 
  





List of figures 
Figure 1.1  A phylogenetic inference of HIV- 1 group M, N, O and the recently discovered 
group P rooted with SIV variants of non-human primates.. .......................................... 36 
Figure 1.2 Geographical distribution of the pandemic HIV-1 group M subtypes. .................. 38 
Figure 1.3 A schematic illustration of a single mature RNA virion). ...................................... 40 
Figure 1.4 Schematic illustration of HIV-1 genome organization. ......................................... 41 
Figure 1.5 Illustration of HIV replication cycle ...................................................................... 48 
Figure 2.1 A map showing the different health districts around Yaounde/Cameroon ........... 67 
Figure 2.2 An illustration of procedures and molecular techniques used for sample 
processing and analyses in the study Cohorts. ............................................................ 68 
Figure 2.3 A graphic representation of the Becton Dickinson FACS count software algorithm 
evaluating cluster of CD4+ T-cells ............................................................................... 74 
Figure 2.4 HXB2 gene map showing the pol genome. ......................................................... 77 
Figure 3.1 Partial pol (PR) fragment in 1.0% TAE agarose gel picture.. ............................... 94 
Figure 3.2 Partial pol (RT) fragment in 1.0% TAE agarose gel picture.. ............................... 95 
Figure 3.3 Partial pol IN fragment in 1.0% TAE agarose gel picture. ................................... 95 
Figure 3.4 An example of a clean chromatogram ................................................................ 97 
Figure 3.5 Nucleotide sequences of RT fragment ................................................................ 98 
Figure 3.6 An example of sample sequence (CM-21) subtyped as HIV-1 subtype A1 ....... 100 
Figure 3.7 Sample CM_21 screened rapidly for intersubtype recombination using RIP online 
program.. ................................................................................................................... 101 
Figure 3.8 An example of sample sequence (CM-21) of 609 bps in length subtyped as HIV-1 
subtype A1 ................................................................................................................ 102 
Figure 3.9 A sample sequence (Sample_SubO) assigned based on 312bp with a bootstrap of 
less than 70.0%. ........................................................................................................ 108 
Figure 3.10 HIV-1 group O screened using RIP subtyping program.. ................................ 108 





Figure 3.11 Phylogenetic relationship of the pol (RT) gene fragment. ................................ 110 
Figure 3.12 A phylogenetic subtree indicating HIV-1 group M subtype G .......................... 111 
Figure 3.13 A phylogenetic subtree indicating HIV-1 group M subtype F1 ......................... 112 
Figure 3.14 A phylogenetic subtree indicating HIV-1 group M subtype C .......................... 113 
Figure 3.15 A phylogenetic subtree indicating HIV-1 group M subtype A1 ......................... 113 
Figure 3.16 Summary of minor PI RAMs observed in 25 out of 29 sequences analysed. .. 116 
Figure 3.17 Summary of NNRTI observed in 11 out of 27 RT sequences with E138A and 
V179E mutations with high frequency of occurrence. ................................................. 119 
Figure 3.18 Observed drug resistance against RTIs (NRTI and NNRTIs). ......................... 120 
Figure 6.1 Partial pol (PR) fragment in 1.0 % TAE agarose gel picture. ............................. 141 
Figure 6.2 Partial pol (RT) fragment in 1.0 % TAE agarose gel picture. ............................. 141 
Figure 6.3 An example of Nucleotide sequences of PR fragment from 18 adult patients ... 142 
Figure 6.4 An example of sample sequence (PR_SN52) of 477 bp in length subtype 
assigned is pure HIV-1 subtype A (A1) colored red in the pol genome. ..................... 150 
Figure 6.5 An example of sample sequence (PR_SN52) ................................................... 151 
Figure 6.6 Sample PR_SN52 screened rapidly for intersubtype recombination using RIP 
online program. .......................................................................................................... 152 
Figure 6.7 A neighbor-Joining phylogenetic reconstruction of pol (RT) taxa using Tamura-Nei 
model and a bootstrap of 1000 replications.. ............................................................. 154 
Figure 6.8 Observed NRTI and NNRTI drug resistance in adults with over 83.0% susceptible 
to commonly used cART. ........................................................................................... 155 
 





CHAPTER 1 Introduction and literature review 
 INTRODUCTION ............................................................................................................................ 31 
 LITERATURE REVIEW ..................................................................................................................... 33 
1.2.1 Origin of HIV ..................................................................................................................... 33 
1.2.2 HIV diversity ...................................................................................................................... 34 
1.2.3 HIV infections in Humans ................................................................................................ 36 
1.2.4 HIV global distribution ...................................................................................................... 38 
1.2.5 HIV-1 structure and genomic organization ...................................................................... 39 
1.2.5.1 Polymerase............................................................................................................................................... 42 
1.2.5.2 Protease .................................................................................................................................................... 42 
1.2.5.3 Reverse Transcriptase ............................................................................................................................... 43 
1.2.5.4 Integrase ................................................................................................................................................... 44 
1.2.5.5 Other structural genes ............................................................................................................................. 45 
1.2.5.6 Regulatory, accessory and secondary protein structures ........................................................................ 45 
1.2.6 HIV-1 Replication cycle ..................................................................................................... 45 
1.2.7 HIV-1 immunopathogenesis ............................................................................................. 49 
1.2.8 Natural resistance ............................................................................................................ 50 
1.2.9 HIV-1 treatment ................................................................................................................ 52 
1.2.10 Mechanism of cART action ............................................................................................. 55 
1.2.10.1 Viral entry/Fusion inhibitors .................................................................................................................. 55 
1.2.10.2 Protease inhibitors ................................................................................................................................. 55 
1.2.10.3 Reverse Transcriptase inhibitors ............................................................................................................ 56 
1.2.10.4 Integrase inhibitors ................................................................................................................................ 57 
1.2.11 HIV drug resistance (HIVDR) ........................................................................................... 57 
1.2.12 Drug resistance testing ................................................................................................... 59 





1.2.13 HIV infection in Cameroon .............................................................................................. 60 
1.2.14 Aim and specific objective of the study .......................................................................... 62 
  






Human Immunodeficiency Virus (HIV) is the causative agent of Acquired 
Immunodeficiency Syndrome (AIDS) in humans (Weiss, 1993; Douek et al., 2009). 
The HIV/AIDS pandemic has continued to be a major global health problem ever 
since the first case was identified in 1981, (Gottlieb et al., 1981; Barré-Sinoussi et al., 
1983). By end of 2016, sub-Saharan Africa remained the worst hit accounting for 
almost two thirds (25.6 million) of the world’s 36.7 million people living with the virus 
[(WHO, 2017: http://www.who.int/mediacentre/factsheets/fs360/en/)]. The West and 
Central African sub-region accounted for 16.6% of the global tally. Approximately 
310, 000 infected individuals succumbed to AIDS-related illnesses, and 370, 000 of 
the world’s 1.8 million new HIV cases were reported in the same region in 2016 
[(UNAIDS, 2017- http://www.unaids.org/sites/default/files/media_asset/20170720 
_Data_book_2017_en.pdf)]. In Cameroon, approximately 560,000 (470, 000 to 
650, 000) adults aged 15 to 49 years were living with HIV; a prevalence rate of about 
3.8% (3.1% - 4.5%) [(UNAIDS, 2017: HIV and AIDS estimates, 2016 -
http://www.unaids.org/en/regionscountries/countries/cameroon/)]. In children of 0 – 
14 years from Cameroon, HIV infections was about 46,000 (35,000 – 57,000) 
[(UNAIDS, 2017: HIV and AIDS estimates, 2016 -http://www.unaids.org/en/ 
regionscountries/countries/cameroon/)]. Since the introduction of combination 
antiretroviral therapy (cART), there has been a decline of new HIV infections and 
related deaths globally. In 2016, 19.5 million people globally were able to access 
cART; up from 15.8 million in June 2015 - a 19.0% increase [(Penazzato et al., 2015; 
UNAIDS, 2017: Fact Sheet, 2017- http://www.unaids.org/sites/default/files/media 





_asset/UNAIDS_FactSheet_en.pdf – accessed on 20th October, 2017]. According to 
World Bank data report based on UNAIDS estimates, the cART coverage in 
Cameroon was about 30.0% in 2016 [(World Bank - 
https://data.worldbank.org/indicator/SH.HIV.ARTC.ZS?locations=CM]. Many HIV 
positive patients are now experiencing a healthy and longer life expectancy. 
Unfortunately, there is still continuous spread of HIV and more so from expectant 
mothers to their unborn children (Sama et al., 2017). One of the contributory factors 
for continued spread of the virus is its diverse nature. As will be discussed in section 
1.2.4, certain subtypes of HIV spread faster as they easily adapt in their new host. 
Cameroon is known to harbour majority of diverse HIV groups and subtypes, and this 
could be the reason why new HIV infections are being experienced (Agyingi et al., 
2014; Faria et al., 2014). The upscale of cART coverage with non-adherence to the 
prescribed regimen has also led to HIV drug resistance (HIVDR) further fuelling HIV 
spread (Gordon et al., 2015; Fonsah et al., 2017). The emergence and increase of 
HIVDR globally is a serious threat for the overall success of comparting the HIV 
pandemic and this requires continuous surveillance (Aghokeng et al., 2013). Many 
countries in sub-Saharan Africa have reported approximately 10.0% HIVDR in therapy 
naïve patients [(http://nicd.ac.za/assets/files/NICD%20Communicable%20 - 
Diseases%20Communique_Mar2016_final.pdf)]. In Cameroon, HIVDR rates for 
therapy naïve population are at 3.8% and 3.6% for adults and children respectively 
(Billong et al., 2013). The World Health Organization (WHO) is currently supporting 
surveillance programmes for HIVDR by developing an HIVDR database. The 
database focuses on (1) supporting countries and genotyping laboratories to produce 
high-quality reports through quality assurance of epidemiological and sequencing 





data, linking to the most recent Stanford HIVDR interpretation algorithms 
[(https://hivdb.stanford.edu/) – accessed on 3rd February 2017], to provide 
standardized HIVDR interpretations, (2) support dissemination of data for global 
reporting and, (3) provide countries with a long-term secure repository for their 
HIVDR data [(hiv-aids@who.int)]. The HIVDR surveillance program play a key role in 
managing the HIV pandemic, but in a resource-limited country like Cameroon, 
implementing such programs is expensive and rarely available.  
 Literature review 
This section covers the origin and diversity of HIV and how it crossed into humans 
from presumably the non-human primates until it became a global pandemic. The 
cross-species transmission of HIV into humans has been attributed to its ability to 
adapt, replicate and mutate very fast, giving rise to various subtypes that are 
currently circulating globally. This section also describes the HIV type 1 (HIV-1) 
structure, genome organization and its life cycle as they play a vital role in drug 
resistance. 
1.2.1 Origin of HIV    
Through molecular clock and phylogenetic analyses, HIV is estimated to have 
originated from sub-Saharan Africa around 1931 (Zhu et al., 1998; Salemi et al., 
2001). It is believed that the virus resulted from multiple zoonotic cross-species 
transmission events from Simian Immunodeficiency Virus (SIV) infected non-human 
primates found in the West-Central Africa region (Hahn et al., 2000; Taylor et al., 
2008). The earliest documented reports that predate the origin of HIV-1 were of an 





infected adult male plasma and tissue samples taken in 1959 from Kinshasa - the 
capital city of the Democratic Republic of Congo DRC (Zhu et al., 1998; Worobey et 
al., 2008). The pandemic lineage of HIV-1 group M has been associated with SIV 
variant (SIVcpz) found in chimpanzees (sub-group; Pan troglodytes troglodytes) from 
Southern Cameroon (Keele et al., 2006; Van et al., 2007). The non-pandemic 
variants of HIV-1 groups N (non-M/non-O), O (Outlier) and P (which are associated 
with SIV variants in gorillas) are confined within Central and West Africa (Plantier et 
al., 2009; Vallari et al., 2011). Another SIV (SIVsmm) found in wild sooty mangabey 
monkeys (Cercocebus atys atys), also from West Africa is most closely related to two 
strains of HIV-2 (A and B) and probably transmitted HIV-2 (Apetrei et al., 2004). HIV 
belongs to a group of retroviruses (Retroviridae family) and genera Lentivirus - which 
literally means “a slow virus’. As for all viruses of the Retroviridae family, they attack 
the immune system allowing opportunistic infections and rare malignancies to thrive, 
and if not treated, infection can lead to early death (Okome-Nkoumou et al., 2014; 
Germany Advisory Committee Blood, 2016). The first reported outbreak of HIV/AIDS 
in Africa was from a heterosexual population of the Democratic Republic of Congo 
(DRC). From here, HIV is believed to have spread to other parts of the region (Piot et 
al., 1984).  
1.2.2 HIV diversity 
Based on genetic similarities, HIV has been phylogenetically classified into two 
distinct Types: HIV type 1 (HIV-1) and HIV type 2 (HIV-2). The nature of HIV is that it 
mutates very rapidly and is characterized by extensive heterogeneity that reflects a 
dynamic evolutionary process that is continuously generating new subtypes and 





several new recombinant forms (Roberts et al. 1988; Lemey et al., 2006). The 
observed extensive genetic diversity results from many probable events, including a 
rapid replication cycle, function of point mutations, recombination of different strains, 
proofreading inability of RT that leads to high error rate and selective immune 
pressures from the host (Roberts et al., 1998; Lessells et al., 2012; Tongo M. and 
Burgers W., 2014). Genetic differences between HIV-1 and HIV-2 are approximately 
45.0 – 50.0%. HIV-1 has been phylogenetically classified into four distinct groups; 
Group M (Main/Major), Group O (outlier), Group N (Non-M/Non-O) and Group P 
(Plantier et al., 2009; Sharp et al., 2011). The genetic difference among these HIV-1 
groups is approximately 35.0% (Korber et al., 2001). HIV-1 group M has been 
subdivided further into nine distinct non-recombinant subtypes/clades denoted with 
letters, A-D, F-H, J-K as indicated in Figure 1.1, with over eighty Circulating 
Recombinant Forms (CRFs) and several Unique Recombinant Forms (URFs) 
(https://www.hiv.lanl.gov/content/sequence/HIV/HIVTools.html). 
  





Figure 1.1  A phylogenetic inference of HIV- 1 group M, N, O and the recently 
discovered group P rooted with SIV variants of non-human primates. HIV-1 
group M subtypes are denoted with letters; A-D, F-H and J (Plantier et al., 2009; 
Vallari et al., 2011). 
The nine HIV-1 group M subtypes are equidistant from one another, with the pol 
gene remaining conserved, while there is an average inter-subtype genetic variability 
of 15.0% for the gag gene and 25.0% for the env gene (Robertson et al., 2000; Spira 
et al., 2003). HIV-2 has been classified into eight non-recombinant subtypes; A-H 
with one recombinant form, namely HIV2_CRF01_AB (Clavel et al., 1986; 
(https://www.hiv.lanl.gov/content/sequence/HIV/HIVTools.html)). 
1.2.3 HIV infections in Humans 
The first clinical cases of HIV were diagnosed in men having sex with men (MSM) in 
Los Angeles, United States of America (USA) in 1981 (Gottlieb et al., 1981). These 
men developed a rare lung infection (Pneumonia) caused by a fungi called 
Pneumocystis carinii. Other groups of men in New York and California were also 





found with an aggressive skin cancer known as “Kaposi’s Sarcoma” caused by 
Human Herpes Virus 8 (HHV-8) (Hymes et al., 1981). These diseases found to be 
common in people with impaired immunity, was subsequently defined as Gay 
Related Immune Deficiency (GRID) (CDC, 1982). Up until this point, the causative 
agent was unknown and efforts for its discovery began. In 1983, Luc Montagnier and 
Françoise Barré-Sinoussi from the Pasteur Institute in France isolated the virus and 
named it “Lymphoadenopathy Associated Virus (LAV)” (Barre-Sinoussi et al., 1983). 
The virus was found to infect cells of immune system and eventually leading to death. 
Soon after, cases of infection were detected in IDUs, Haitians, and heterosexuals 
(Pape et al., 1983; Bloom, 1984). This confirmed that the disease was also 
transmitted through blood contact. In June 1983, HIV was found in children (Oleske 
et al., 1983) and later confirmed that they may have acquired it directly from their 
mothers before, during or shortly after birth (CDC, 1983). Broder and Gallo (1984)] at 
the National Cancer Institute in USA, isolated a virus they called “Human T cell 
Lymphotropic virus (HTLV III). The LAV and HLTV III were found to be similar (Marx 
et al., 1984). Unfortunately, the HTLV III was co-infected with Human T cell Leukemia 
virus (HTLV) and therefore, Gallo was not honoured with the Nobel price (Gallo et al., 
1983). In 1986, HIV-2 was also isolated from the West African region (Hughes A. and 
Corrah T., 1990; Clavel F. et al., 1986). In May 1986, the international Committee on 
Taxonomy of viruses officially renamed the virus “Human Immunodeficiency Virus” as 
it is known to date (Case et al., 1986).  





1.2.4 HIV global distribution  
The pandemic HIV-1 group M subtypes is spread globally (Hemelaar et al., 2011) 
and the greatest diversity of its subtypes and recombinants are found in Central-West 
Africa, as shown in Figure 1.2.   
 
 
Figure 1.2 Geographical distribution of the pandemic HIV-1 group M subtypes. 
Each different colour of the superimposed pie chart represents a different HIV-1 
group M subtype found within that region. Cameroon, which is part of Central Africa 
sub-region harbours majority of HIV-1 group M subtype: A,C,D,G,H and J; 
Circulating recombinant forms like CRF01_AE and CRF02_AG, and other rare 
subtypes as indicated by the arrow (Source:  Hemelaar et al., 2011).  
The lesser virulent groups of HIV-1; namely group O, N and P, are also confined to 
Central-West Africa; especially Cameroon and the surrounding countries (Vallari et 
al., 2011; Ayouba et al., 2000). Group M, subtype C accounts for almost 50.0% of 
global infections and is common in India and South Africa. Subtype A accounts for 





12.0% and predominates the East Africa axis, while subtype B (10.0%) is common in 
the Americas and Europe. Subtype G and CRFs, which are common in Central-West 
Africa, accounts for 6.0% and 5.0% of global infections, respectively. Paradoxically, 
regions like Central-West Africa with the greatest diversity, experience less HIV 
pandemic. Other subtypes like F, H, J, K and recombinants account for 
approximately 13.0% (Hemelaar et al., 2011; Lau & Wong, 2013). Group O, which is 
second in the global spread after the group M pandemic, was discovered in 
Cameroon in 1998. Globally, group N has been reported in less than 20 individuals; 
while, group P - that was discovered in 2009, has been reported in less than 2 
individuals. Both HIV-1 and HIV-2 and majority of HIV-1 groups, have been found in 
Cameroon apart from one group N isolate (Plantier et al., 2009; Sharp et al., 2011).  
1.2.5 HIV-1 structure and genomic organization 
HIV is an enveloped virus measuring approximately 100-120nm in diameter, 
spherical in shape with an associated matrix. The matrix is covered by a bi-lipid 
membrane layer where viral spikes of glycoprotein 120/Surface Protein (gp 120, SU) 
are attached. The matrix encloses the capsid (p24 CA) which comprises of 
approximately 2000 gag protein copies. The viral genome is enclosed by the capsid 
and consists of two identical copies of unspliced positive single stranded RNA that 
are non-covalently linked, weighing about 9.7 kilo base pair (kb) (Korber et al., 2001). 
Figure 1.3a shows a mature HIV structure.  






Figure 1.3a. A schematic illustration of a single mature RNA virion showing; 
Structural proteins that consist of (i) Env glycoprotein- surface glycoprotein 
(gp120 SU) and the attached transmembrane glycoprotein (gp41 TM). (ii) Gag 
polyprotein- matrix protein (p17), Capsid protein (p24) and Nucleocapsid 
protein (p9). The Pol proteins- protease (p10), Reverse transcriptase 
(p66/p51) and Integrase (p31). The viral RNA indicated at the center consists 
of two copies of unspliced positive single stranded RNA tightly attached to the 
Nucleocapsid protein (p9). Source: Nature Review: Available at: 
http://www.nature.com/nri/journal/v2/n4/fig_tab/nri776_F1.htm). 
A characteristic of retroviruses is that the genetic information is stored in the RNA 
genome (Figure 1.3b) and it encodes for nine genes namely: group specific antigens 
(Gag), Polymerase (Pol), Envelope (Env), trans-activator of transcription (tat), 
regulator of expression of viral proteins(rev), Negative factor (Nef), Virion infectivity 





factor (vif), Viral protein r (vpr) and Viral protein unique (vpu). These nine genes are 
found along three overlapping Open Reading Frames (ORFs) and are grouped into 
three categories of proteins: structural proteins (Gag, Pol, and Env), regulatory 
proteins (Tat and Rev) and accessory proteins (Nef, Vif, Vpu and Vpr). At both 5’ and 
3’ ends, the RNA genome is flanked by two identical nucleotide sequence repeats 
known as “long terminal repeats (LTRs)” of approximately 640 base pairs (bps) in 
length.   
 
Figure 1.3b. Schematic illustration of HIV-1 genome organization. The RNA 
genome is approximately 9.7 kb flanked with two LTRs at 5’-3’ end. The env 
and gag genes codes for structural proteins while, pol gene codes for essential 
viral enzymes. Accessory genes include; the nef, tat and rev and are required 
for the control of viral gene expression. The vif, vpr and vpu are required for 
viral infectivity, assembly and release. (Yasutsugu and Youichi, 2011). 





1.2.5.1 Polymerase  
The Polymerase gene (Pol) plays a very important role in the production and 
functioning of new virions through synthesis of proviral Deoxyribonucleic acid (DNA), 
viral genomic integration and maturation. The Pol is expressed as a Gag-Pol 
precursor (Pr160), which during viral maturation process is cleaved to a Pol 
polypeptide protein. The polypeptide protein is further cleaved into functional viral 
enzymes - Protease (PR), Reverse Transcriptase (RT), Integrase (IN), RNase H and 
a transframe protein (TF/p6) (Jack et al., 1988; Oroszlan et al., 1990). For the 
purpose of this study, only the three enzymes- PR, RT and IN will be focused on. The 
pol gene is highly polymorphic, rendering it important in HIV characterization. 
Furthermore, majority of commonly used cART are designed to target the pol 
genome so as to slow viral progression and transmission (Gea- Banacloche et al., 
2000; Corado et al., 2017). 
1.2.5.2 Protease  
The PR is a homodimer structure consisting of two non-covalently similar monomer 
structures of 99-138 amino acid (aa) residues in length. Each monomer has an 
extended glycine–rich loop that act as an active site for substrate binding (James & 
Sielecki, 1985). The Protease (PR) has a molecular weight of 11-15 kilo Dalton (kDa) 
and it is maximally active in acidic environment of ph 4.5-6.5. Furthermore, during the 
HIV-1 life cycle, the PR enzyme (that is part of the aspartyl protease group) plays a 
critical role in the budding and maturation process of the new viral particle. The PR 
cleaves Gag and the Gag-pol polyprotein precursor (Pr160) to produce functional 





structural proteins and enzymes necessary for virion development and maturation 
(Pettit et al., 2004). A stable RNA structure and a heptanucleotide slippery sequence 
(UUUUUUA) mediates ribosomal frameshift at the intersection of the 3’ end of Gag 
and Pol to change the reading frames for a different translation to obtain Gag and Pol 
functional proteins (de Oliveira et al., 2003; Mazauric et al., 2009). The structural 
information on the PR enzyme has led to the development of class of antiretroviral 
compounds as discussed in section 1.8.2, which are directed at inhibiting the HIV-1 
PR activity. 
1.2.5.3 Reverse Transcriptase  
This is an enzyme encoded by the pol gene and consists of two subunits with a 
molecular weight of 66 and 51 kDa. It is found in all retroviruses and is necessary for 
the synthesis of new virion particles during a process known as reverse transcription. 
Three major biochemical activities characterize the nature of the Reverse 
Transcriptase (RT) enzyme and it includes RNA-DNA-dependent, DNA-dependent 
polymerase activity and ribonuclease H activity. The RT enzyme performs error-
prone reverse transcription as it does not have 3’-5’ exonucleolytic proof reading 
activity. These errors lead to numerous viral genomic point mutations generating new 
copies of HIV genomes with a diverse genetic variation (Oelrichs et al., 2000). The 
RT polymerase activity generates a complementary DNA (cDNA) from the single 
stranded genomic RNA found within the virion particle. During this time of cDNA 
synthesis, the RNase H removes the original RNA template that acted as the primer. 
The synthesized cDNA is a long and complex protein molecule that the RT enzyme 
further converts into a double helix form, which is the normal structure state of the 





DNA (Götte et al., 1999). The RT enzyme performs error-prone reverse transcription 
as it does not have 3’-5’ exonucleolytic proof reading activity. These errors lead to 
numerous viral genomic point mutations generating new copies of HIV genomes with 
a diverse genetic variation (Oelrichs et al., 2000). Some of the molecular assays such 
as the polymerase chain reaction (PCR) and DNA analyses, use RT from Avian 
Myeloblastosis Virus (AMV) and Moloney Murine Leukemia Virus Reverse (M-MLV) 
as the basis for cDNA synthesis. The AMV and M-MLV are also retroviruses like the 
HIV (Yasukawa et al., 2008). In HIV treatment, some of the commonly used cART, 
have been designed to target the RT region to stop further replication and 
transmission (Sarafianos et al. 2009, Men´endez-Arias, 2013). These classes of 
drugs will be discussed under cART drug mechanism action in section 1.2.10.  
1.2.5.4 Integrase  
The Integrase (IN) is a 32 kDa protein structure consisting of 288 aas. The IN is 
synthesized by the viral protease enzyme during the maturation process (Chiu & 
Davies, 2004). It plays a critical role in viral development by mediating integration of 
synthesized HIV-1 proviral viral DNA into host cell genome. (Mushahwar and Isa, 
2007; Ombretta et al., 2012). During this integration, the Integrase (IN) displays three 
major activities of (1) two nucleotide trimming at 3’ end of the linearized viral DNA, (2) 
cleaves the double stranded host cell DNA through endonuclease activity to allow 
integration of the trimmed viral DNA, and (3) providing a single covalent bonding at 
the integrated site through ligase activity (Bushman et al., 1990). The integration site 
is thought to be influenced by the accessibility of the chromosomal DNA found within 
the chromatin. Integration of the viral DNA into host cell DNA genome allows efficient 





expression of viral genes. Current development of some antiretroviral class of drugs 
has been directed towards inhibiting this integration process, thereby limiting further 
production of new viral copies, as discussed in section 1.8.4. 
1.2.5.5 Other structural genes 
gag gene: The gag gene codes for the Gag protein that consist of Matrix (MA, p17), 
viral capsid (CA, p24), [Spacer peptide1 (SPI)], P1), Spacer peptide 2 (SP2), 
Nucleocapsid (NC), P7) and P6 proteins. The MA provides viral integrity while the NC 
prevents nucleases from digesting the RNA. The gag gene plays a very important 
role in viral assembly (Gheysen et al., 1989). 
env gene: The env gene forms glycoproteins that consist of a surface glycoprotein 
(gp120 SU), transmembrane glycoprotein (gp 41 TM), fatty lipid bilayer and host cell 
protein. The gp120 surface glycoprotein and gp41 are essential for viral attachment 
and fusion before the viral capsid enters the host cell for production of more viruses. 
1.2.5.6 Regulatory, accessory and secondary protein structures 
Regulatory proteins, Tat and Rev, are important players in gene expression and viral 
propagation as they target host cells through modulation of transcription and post-
transcription. Accessory genes – the vif, vpr, vpu and nef are necessary for viral 
virulence and improve the efficiency of the viral replication process.  
1.2.6 HIV-1 Replication cycle 
HIV is present in body fluids of infected individuals as both free viral particles and 
virus within living cells. Furthermore, during HIV-1 replication cycle, the viral genome 





is integrated into the host-cell genome (integrated provirus) that becomes a viral 
reservoir. The viral replication cycle is divided into seven stages as illustrated in 
Figure 1.5, starting with a mature HIV-1 particle recognizing and attaching onto the 
target cell, usually CD4+ T-cells. This attachment is mediated by interaction between 
the virus’ extracellular domain of gp120 and the host cell receptors (Dash et al., 
2008). Viral attachment is followed by additional interactions with chemokine 
receptors like the CCR5, CXCR4 or in some instances the CCR3 chemokine co-
receptor (Chan and Kim, 1998; Clapham and McKnight, 2002) (step 1, Figure 1.5). 
The binding of gp120 to CD4+ T-cells results in a conformational change resulting in 
the fusion of both cell’s membranes. This fusion leads to formation of viral synapses 
necessary for efficient entry of the viral genome and its enzymes into the host cell 
cytoplasm (Arthos et al., 2008) (step 2, Figure 1.5). In the cytoplasm, the viral single 
stranded RNA is converted to double stranded DNA by the viral transcribed RT 
enzyme (Zheng et al., 2005) (step 3, Figure 1.5). This stage of reverse transcription 
is extremely prone to errors as the enzyme does not have a 3’ to 5’ proof reading 
capability. These errors result in RAMs and allow for virus immune escape causing 
drug resistance and participating to viral diversity. The newly synthesized viral DNA 
(provirus) is imported to the nucleus by the IN enzyme and is covalently integrated 
into the host DNA (step 4, Figure 1.5). The IN inhibitors (INIs) interfere with 
integration of the provirus into the host cell DNA, blocking viral replication as will be 
described under mechanism of cART action in section 1.8.4. The provirus has the 
ability to lay dormant resulting in a latent infection; a barrier towards cure (Siliciano et 
al., 2003; Zheng et al., 2005). The DNA provirus in activated host cells is transcribed 
producing mRNA transcripts, which are capped at the 5’ end and polyadenylated at 





the 3’ end (step 5, Figure 1.5). Three splicing events takes place on the mRNA 
transcripts resulting to completely spliced, singly spliced and unspliced mRNAs. The 
completely spliced mRNAs are translated into regulatory proteins, like the Tat and 
Rev. The Tat protein initiates transcription by attaching to the trans-activating 
response element (TAR) at the 5’ LTR with association of other cellular proteins like 
cyclin T and cyclin-dependent protein kinase-9 for new virus production (Wei et al., 
1998). The singly spliced mRNAs, which encode for Vpr, Vpu and Env viral proteins 
and unspliced mRNAs encoding for Gag (pr55), Gag-Pol (pr160) viral proteins, are 
exported to the cytoplasm by Rev. The Env precursor polyprotein (gp160) is 
synthesized in the endoplasmic reticulum (ER) from the singly spliced env mRNA and 
modified post-translationally in both the ER and Golgi apparatus (Wyatt & Sodroski, 
1998). The gp160 is then cleaved by cellular proteases to produce glycoproteins 
gp120 and gp41 before transported to the plasma membrane for viral assembly (step 
6, Figure 1.5). In the ribosomes, the Gag polyprotein (pr55 Gag) is synthesized using 
unspliced mRNAs as the message and with small amounts of Gag-Pol precursor 
proteins that have undergone a translational frameshift. They are incorporated onto 
the plasma membrane of the immature viral particle (Klimas et al., 2008). Gag 
molecules attract two copies of unspliced viral genome, encapsidating them onto the 
the plasma membrane of the already forming immature viral particle. The immature 
viral particle buds out of the host cell plasma membrane where cellular PR cleaves it, 
forming an infectious mature virion (step 7, Figure 1.5).  






Figure 1.4 Illustration of HIV replication cycle showing HIV particle binding, fusion 
and entry into the target cell (CD4 cell). After entry, reverse transcription takes place 
followed by integration of the viral genome onto host genome. Replication, assembly 
and budding of the mature viral particle completes the life cycle, and the new virus 
particle is ready to infect other target cells. Current ART regimen commonly used 
target the reverse transcription (NRTI and NNRTI), Integration (IN inhibitors) and 
budding (PI) phases. (https://aidsinfo.nih.gov/education-materials/glossary/1596/life-
cycle). 
 





1.2.7 HIV-1 immunopathogenesis 
HIV-1 immunopathogenesis involves a number of viral and host factors that interact 
in a complex manner resulting in HIV entry and the start of disease progression 
(Stevenson, 2003; Forsman & Weiss, 2008). The HIV-1 attaches to receptors on the 
surface of CD4+ T-cells and macrophages gaining entry onto the cell. The viral entry 
attachment can also be through the chemokine co-receptors (CCR5 or CXCR4). This 
attack on host immune cells results in a continuously activated immune system that 
eventually becomes compromised (Cunningham et al., 2010). Eventually, 
opportunistic infections and malignancies thrive, leading to AIDS (Davaro and 
Thirumalai, 2007). Clinically, HIV-infected patients, progress from an initial HIV 
infection to HIV/AIDS at different rates – the rates depends on various mechanisms 
of interaction between the patients’ immunological factors and the viral regulatory and 
accessory proteins. These patients can be classified as rapid progressors 
(approximately 10.0%) developing AIDS within the first 2-3 years of infection or, 
typical progressors developing AIDS within a period of approximately 10 years from 
initial infection or long-term non-progressors (LTNPs) (<5.0%) who do not show 
symptoms at any time of the infection with stable CD4+ T-cells counts (Panteleo and 
Fauci, 1995; Levy, 2007). HIV infection has four distinct developmental phases: (1) 
primary infection or the seroconversion phase (2) clinically asymptomatic/latency 
phase (3) symptomatic and (4) chronic phases (Embretson et al., 1993; Koup et al., 
1994). The primary phase lasts for a few weeks after initial infection and may be 
accompanied by a short flu-like illness, while many remain asymptomatic (Schacker 
et al., 1996). There is large amount of HIV-infected peripheral blood mononuclear 





cells (PBMCs) and high viremia observed (Graziosi et al., 1993). The body defends 
itself by producing HIV antibodies and cytotoxic lymphocytes – marking the 
seroconversion process. HIV diagnosis can be missed before seroconversion is 
completed. The asymptomatic or latency phase is characterized by low viremia 
caused by increased specific cytotoxic activity. Patients don’t show signs of damaged 
immune system, although it is believed that HIV continues to actively replicate 
especially in the lymph nodes. During the symptomatic phase there is progressive 
immune deterioration characterized by multi-system disease as the patient is 
vulnerable to opportunistic infections, marking the onset of AIDS (Panteleo and 
Fauci, 1995). The chronic stage of HIV-1 infection is the last stage and is 
characterized with very low CD4+ cell count and highly elevated viral load. Various 
opportunistic infections and malignancies are manifested, and the patient can 
succumb to death if not treated.  
1.2.8 Natural resistance 
Some individuals infected with HIV-1, especially the LTNPs, show partial or complete 
natural resistance against the virus (Hunt et al., 2009; Kumar, 2013). Resistance to 
HIV-1 infection has been attributed to natural host restriction factors like Tetherin, 
Apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) 
and Tripartite motif proteins (TRIM5α), antagonistic to viral proteins like Vif, Vpu, Nef 
and Envelope proteins. This antagonism limits viral replication, viral assembly, 
budding and infectivity. The APOBEC3G for example, inhibits provirus integration into 
host cell genome in Vif-free HIV-1. When viral particles without Vif protein bud, they 
encapsidate the inhibitory APOBEC3G proteins leading to excessive cytidine to 





uridine hypermutation. This usually occurs in the newly infected cells and in the 
negative sense reverse transcripts (Sheehy et al. 2002; Malim, 2006). In the positive 
cDNA strand a guanosine to adenosine mutations is registered and all this leads to 
functional imbalance between Vif and APOBEC3G proteins. Usually Vif and 
APOBEC3G functions are antagonistic to each other and any imbalance will 
negatively affect the viral fitness in infecting new cells (Arriaga et al., 2006). The 
TRIM5α motif is a protein factor that inhibits retrovirus replication (Stremlau et al., 
2004). Therefore, a mutation in the SPRY domain of TRIM5α and other associated 
proteins has been shown to improve antiretroviral activity (Nakayama et al., 2005). 
Natural resistance to HIV-1 has also been associated with three variants of CCR5 co-
receptors (CCR5-Δ32, SDF1-3’A and CCR2-64I) (Nkenfou et al., 2013). The CCR5 is 
a chemokine receptor in the host cell involved in the binding of viral envelope 
proteins during viral entry. If a mutation occurs on the CCR5 protein it greatly reduces 
chances of viral attachment and entry into the host cell. Individuals who express 
homozygote state for CCR5-Δ32 appear to have natural resistance against HIV 
strains using the CCR5 co-receptors for entry into the host cell (Galvani et al. 2005; 
Hütter et al., 2009). The CCR5-Δ32 allele is high (5.0-15.0%) in Northern Europe, 
while mostly absent in Africans and East Asians (de Silva., 2004). Some individuals 
with Human Leucocyte group antigens like Antigen (HLA)-A2/6802 have reduced risk 
to HIV-1 infections (MacDonald et al., 2001). HLA-A2/6802 contains conserved 
immunogenic epitopes that are similar to HIV-1 peptide epitopes for T cell 
recognition. This means that both HLA-A2/6802 and HIV-1 compete for T cell 
recognition reducing HIV-1 susceptibility. High levels of cystatin is also thought to be 





interfering with HIV replication as was described in Kenyan sex workers who tested 
HIV-1 negative despite being exposed to the virus multiple times. In persistently HIV-
1 infected individuals, cysteine raises intracellular glutathione (GSH) level inhibiting 
HIV-1 replication. (Roederer et al., 1990). 
1.2.9 HIV-1 treatment 
At the start of HIV-1 treatment, antiretroviral drugs were first prescribed as 
monotherapy. Zidovudine (AZT) was the first monotherapy drug to be approved by 
the USA Food and Drug Administration (FDA) for HIV/AIDS treatment and was 
introduced in 1987 (Fischl et al., 1987). However, HIV-1 infections continued to rise 
leading to high mortality and morbidity rates. This meant that monotherapy was not 
effective and a search for alternative ways in ART management began. This led to 
the introduction of a cocktail of ART regimen referred to as “combination antiretroviral 
therapy (cART)” (Collier et al., 1996). A large array consisting of six different classes 
of anti-retroviral drug has been developed targeting various stages of HIV-1 
replication (Figure 1.4) (Larder and Kemp, 1989; Palmisano and Vella, 2011). The six 
antiretroviral classes include viral entry inhibitors (CCR5 antagonists), fusion 
inhibitors, Nucleoside Reverse Transcriptase inhibitors (NRTIs), non-Nucleoside 
Reverse Transcriptase inhibitors (NNRTIs), Protease inhibitors (PIs) and Integrase 
inhibitors (INIs) also known as Integrase strand transfer inhibitors (INSTIs) (Pau and 
George, 2014) and are indicated in Table 1.1. These antiretroviral drugs have been 
approved by the FDA and are initiated with three drugs regimen/cART as 
recommended by WHO– 2 NRTIs + 1 NNRTI/PI as first line of treatment. A second 
line follows with also three drug combinations from the same or different classes in 





case the patient does not respond well to the first line cART. Although cART does not 
eradicate HIV-1 infection completely, it has successfully improved recovery of the 
immune system, reducing HIV-1 transmission and protecting the patient against 
opportunistic infections (Murphy et al., 2001; Seth et al., 2016). However, research is 
ongoing looking into developing a single pill that has all three drug combined to 
increase patient adherence. Raltegravir (RAL, MK-0518) is the first INIs to be 
approved by the FDA in 2007, followed by Dolutegravir (DTG), and Elvitegravir (EVG, 
GS-9137) in 2013 and 2014 respectively. 
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*PIs is usually prescribed with boosted RTV 
Source: FDA-Approved HIV Medicines: Last Reviewed: 
(https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/21/58/fda-approved-hiv-
medicines). 





1.2.10 Mechanism of cART action  
1.2.10.1 Viral entry/Fusion inhibitors 
As the name suggests, entry inhibitors act in preventing viral entry into the host cell 
by blocking host cell receptors. Currently approved viral entry inhibitor drugs include 
Maraviroc (MVC): a CCR5 receptor antagonist, and a fusion inhibitor - enfuvirtide 
(ENF or T-20), which blocks fusion of the virus with the host cell membrane by 
binding to gp41 protein therefore preventing the conformational change necessary for 
membrane fusion (Lieberman-Blum et al., 2008). There have been challenges with 
developing viral entry drug inhibitors due to the evolving variable regions within the 
env gene.  
1.2.10.2 Protease inhibitors 
The protease inhibitors (PIs) are structure-based drugs designed to bind to the active 
site of the Protease enzyme inhibiting viral maturation. Alternatively, the PI is 
designed to mimic the transition state that occurs during peptide cleavage blocking 
the Protease activity (Lv et al., 2015). A number of RAMs, both major and minor, 
found in the pol PR genome region have been associated with reduced susceptibility 
to PI therapy. The major mutations in the pol PR genome have been associated with 
conformational changes that end up improving substrate selection by the viral PR 
enzyme. Likewise, minor mutations in combination with secondary mutations act as 
compensatory mutations that can improve viral fitness. Currently, there are about ten 
approved PIs by the FDA (Wensing et al, 2010) and they include first generation PIs - 
Indinavir (IDU), Ritonavir (RTV) and Saquinavir (SQV) which unfortunately were 





found to have a high pill burden and low bioavailability. This necessitated the 
introduction of second generation of PIs boosted with ritonavir (PI/r) that have high 
genetic barrier to RAMS. This PI/r includes Atazanavir (ATV), Darunavir (DRV), 
Fosamprenavir (FPV), Tipranavir (TPV), Amprenavir and Lopinavir. 
1.2.10.3 Reverse Transcriptase inhibitors 
The Reverse transcriptase inhibitors (RTIs) specifically target and bind to the RT 
enzyme, thereby preventing viral replication. Depending on the mode of action, these 
drugs can be further classified into 2 classes; namely, Nucleoside Reverse 
Transcriptase Inhibitors (NRTIs) and Non-Nucleoside Reverse Transcriptase 
Inhibitors (NNRTIs). NRTI analogues lack a free 3’ hydroxyl group that terminates 
viral transcription of the newly synthesized DNA strand once they are incorporated by 
the viral RT enzyme. The NRTIs analogues include Abacavir (ABC), which is a 
guanosine analogue, Didanosine (ddI) - an analogue for Adenosine, Emtricitabine 
(FTC) and Lamivudine (3TC), which are cytidine analogues, Tenofovir disoproxil 
fumarate (TDF) - an adenosine analogue and Zidovudine (AZT), a thymidine 
analogue. The NNRTIs bind to a hydrophobic region near the active site of the RT 
enzyme, preventing the enzyme from synthesizing new DNA copies. A single 
mutation induced by any of the NNRTIs currently used, can confer cross-resistance 
against all NNRTI drug classes (Clavel and Hance, 2004). This problem has been 
countered by designing new NNRTI drugs like Etravirine (ETR), which are effective 
irrespective of the presence of NNRTI induced mutations. NNRTIs include Efavirenz 
(EFV), Etravirine (ETR), Nevirapine (NVP) and Rilpivirine (RPV).  





1.2.10.4 Integrase inhibitors  
The Integrase inhibitors (INIs) are a class of cART agents that inhibit HIV-1 
replication by interfering with the IN enzyme activity (Hazuda et al., 2004; Evering et 
al., 2007). IN is a 288 aa enzyme that catalyzes the 3’ end and strand transfer of the 
viral DNA during integration into the host cell DNA (Pommier et al., 2005; McColl and 
Chen, 2010). The INIs interfere with IN enzyme activity through strand transfer 
reaction by two mechanisms: (1) by interacting with two essential magnesium metal 
ion cofactors at the active site of the enzyme and (2) by binding to a specific complex 
between the enzyme and viral DNA (Grobler et al., 2002). This mechanism of action 
by INIs is specifically meant to block integration of viral DNA into the host cell DNA, 
thereby preventing viral replication. The FDA-approved INIs include Raltegravir (RAL, 
MK-0518, the first INIs to be approved by FDA in 2007), followed by Dolutegravir 
(DTG), and Elvitegravir (EVG, GS-9137) approved in 2013 and 2014, respectively 
(Steigbigel et al., 2008; Pandey, 2014; Kandel and Walmsley, 2015). These INIs 
seem to be less prone to the development of resistance (You et al., 2016). 
1.2.11 HIV drug resistance (HIVDR) 
Development of HIV drug resistance (HIVDR) has been a major challenge to the 
successful cART management globally (Hamers et al., 2012). HIVDR has been 
associated with the upscale of cART coverage, insufficient patient adherence and 
transmitted drug resistance (Gupta et al., 2012; WHO, 2017 - HIV drug resistance 
report, 2017: http://apps.who.int/iris/bitstream/10665/255896/1/9789241512831-
eng.pdf?ua=1). This is further worsened, especially in resource-limited settings like 





Africa, by minimal drug resistance testing, lack of monitoring of viral loads, improper 
cART prescriptions, failures in patient follow up, frequent drug stock outs and poor 
patient compliance. The emergence of HIV drug resistance results from RAMs that 
affect the ability of cART to effectively block HIV replication. RAMs can either be 
primary or secondary. Primary resistance also referred to as transmitted resistance 
occurs in the event whereby a new HIV-1 infection is caused by a drug resistant 
strain, whereas secondary or acquired resistance is seen when drug resistance 
develops while a patient is on cART (Grant et al., 2002; Bennett et al., 2009). RAMs 
are based on HIV-1 subtype B; although they occur similarly in all subtypes and 
some may occur more frequently than others (Westby et al., 2007). Furthermore, 
some of the RAMS have been found to be polymorphisms that naturally occur in non-
subtype B leading to inconsistencies in reporting drug resistance rates especially in 
areas with high HIV-1 prevalence (Ross et al., 2007). Based on data available on 
HIV-1 subtype B, several RAMs are currently documented and interpreted by public 
database agencies. These agencies include Stanford HIVdb drug resistance 
interpretation algorithm (https://hivdb.stanford.edu/hivdb/by-mutations/); Los Alamos 
National Laboratories HIV Sequence database (www.hiv.lanl.gov, 2017); 
International AIDS Society (IAS) - USA Mutations Associated With Drug Resistance 
(Kantor et al., 2014; Wensing et al., 2017) and French National Agency for AIDS 
Research drug resistant algorithm (http://www.anrs.fr/). There are some 
discrepancies in interpreting various RAMs. A standardized list of RAMs based on 
the HIV-1 pol gene (RT, PR and IN) has been assembled by WHO to act as a 
reference and is continuously updated (Shafer et al., 2007). 





1.2.12 Drug resistance testing 
Drug resistance testing assays currently performed include genotypic, phenotypic 
and tropism assays. These assays assist in monitoring the efficacy of cART used in 
the control of HIV replication or when switching to a new line of treatment. Genotypic 
assays in use such as GenoSurePRIme® offered by Monogram Bioscience provide 
predictions of resistance to all NRTIs, NNRTIs, PIs and INIs. This assay involves 
using genetic material of HIV-1 from patients’ plasma sample to determine a pattern 
of HIV-1 mutations (Shafer, 2002; MacArthur, 2009). The mutations result from 
changes in the HIV-1 genome at specific aa positions and are represented in a code. 
For example, a code such as “K65R”, represents a mutation where the first letter (in 
this case “K”) represents Lysine present in the wild type, the number (“65”) indicates 
the aa position in the gene of interest and the last letter represents the amino acid 
present in the mutant aa – in this case “R”, which is Arginine aa. Genotypic assays 
are cheaper and have shorter turn-around time when compared to phenotypic 
assays; although it is not straightforward to correlate a single mutation and resistance 
to a specific drug (Van Laethem et al., 1999). RAMs are interpreted using different 
algorithms such as the Stanford drug resistance database (HIVDB), which is an 
online program that interprets genotypic resistance tests from the submitted gene 
sequences (Rhee S-Y et al., 2015). The HIVDB results are calculated as a penalty 
score and by adding these scores, the HIVDB algorithm is able to estimate the level 
of susceptibility, which can be interpreted as susceptible or low/intermediate/ high 
level of resistance. Phenotypic assays such as PhenoSense® GT and PhenoSense® 
Integrase offered by Monogram Biosciences are done in the laboratory as in vitro 





assays. These assays measure viral responses against all antiretroviral drugs to 
determine the appropriate cART regimen for the individual patient (Hellmann et al., 
1999). Tropism assays such as Monogram’s Trofile® assays are used in the 
measurement of HIV-1 coreceptor tropism especially when CCR5 inhibitors are 
meant to be used (Aberg et al., 2014). 
1.2.13 HIV infection in Cameroon  
The first HIV-1 case in Cameroon was diagnosed 1985 (Garcia-Calleja et al., 1992; 
Mbanya et al., 2008). From there on, the HIV-1 pandemic has been progressively 
increasing with adult prevalence rates rising from 2.0% in 1990 to a 5.4% peak in 
2000. However, in 2015 the prevalence rate reduced to an average of 4.5% (females 
at 5.6% and males at 2.9%) (Fonsah et al., 2017). This prevalence rate is highest in 
the West and Central African region. Countries like Côte d'Ivoire, Togo and Senegal 
have 3.7%, 2.4% and 0.5% prevalence rates respectively 
(http://data.worldbank.org/indicator/SH.DYN.AIDS.ZS?locations=CM). According to 
estimates by UNAIDS 2015, HIV/AIDS caused between 30,000 to 36,000 deaths and 
290, 000 to 350,000 orphans aged 0 to 17 months [(UNAIDS, epidemic update 
December 2015 - www.unaids.org – accessed on 15th April 2016]. From 1990 - 
2015, the country had about 44 000 new HIV infections with a 0.36% incidence rate 
for adults of 15 - 49 years [(AIDSinfo / UNAIDS, 2015: Global factsheet; 
Epidemiological slides: http://aidsinfo.unaids.org/)]. Cameroon harbours both HIV-1 
and HIV-2, and the majority of HIV-1 groups, subtypes and CRFs are also found here 
(Faria et al., 2014; Agyingi et al., 2014). The HIV-1 group M subtype CRF02_AG is 
described as the most prevalent strain in Cameroon causing over 40.0% of HIV-1 





infections (Aghokeng et al., 2013). Over 90.0% of new HIV-1 infections have been 
attributed to rampant risk sexual behaviour, such as having multiple partners and 
non-use of condoms, which are commonly practised in major cities and towns 
including Yaoundé and Douala. Mother-to-child transmission (also known as perinatal 
or vertical transmission) has contributed to approximately 6.0% of new infections; 
while blood transfusion, drug use and sexual contact have together contributed to the 
remaining 4.0% (UNAIDS Global report, 2016). The high prevalence of HIV-1 in 
Cameroon necessitates an upscale distribution of cART, started in 2003, to ensure 
ease of access of therapy to expectant mothers and children under the prevention of 
Mother-to-child transmission programs (PMTCT) (Billong et al., 2013). According to a 
recent report from UNAIDS, the Center for Disease Control (CDC) together with the 
Cameroonian government established 585 PMCTC clinics across various regions of 
the country [(UNAIDS/WHO, December 2015 – (www.unaids.org) – accessed on 4th 
May, 2016]. This has seen substantial progress in the implementation of the 
simplified WHO approach as the cART services have been decentralized (Aghokeng 
et al., 2013). In 2015, approximately 27.0% of the population had access to cART in 
Cameroon, an increase from 24.0% in 2014 (World Bank- 
(http://data.worldbank.org/indicator/SH.HIV.ARTC.ZS?locations=CM). Despite the 
huge success of cART in Cameroon, it has led to an increased prevalence of HIV 
drug-resistant strains. This has been attributed to insufficient patient adherence or 
incomplete suppression of viral replication during treatment, leading to the 
emergence of drug-resistant viruses (Gordon et al., 2015). In the therapy naïve 
population, HIV-1 drug resistance rates are approximately at 3.8% for adults and 
3.6% in children and infants. HIV diversity, drug resistance and surveillance studies 





are important tools for the implementation of cART, with the aim of managing the HIV 
pandemic. It is often difficult to study HIV resistance RAMs in resource limited 
settings like Cameroon owing to limited number of centers performing HIV-1 a 
resistance testing. Furthermore, diagnostic resistance testing remains costly to 
implement; justifying the limited amount of cART data in naïve and treated children 
and adults in Cameroon. The government of Cameroon has established resistance 
testing laboratory center at The Chantal Biya Hospital in the main city of Yaoundé. 
Although recommendable, more similar centers are required for wide coverage 
especially in the rural areas. 
1.2.14 Aim and specific objective of the study  
In this study, our aim and objectives were to analyze the diversity of HIV-1 and 
resistance patterns from infants/children and adults from the rural and urban 
surroundings of Yaoundé, Cameroon. HIV-1 diversity is thought to have an impact on 
the specificity and sensitivity of diagnostic assays, HIV-1 treatment, vaccine design 
and a possible cause for the emergence of drug resistance (Geretti et al., 2009; 
Martinez et al., 2009). It has also been suggested that different subtypes may be 
transmitted at different rates with different rates of disease progression (Baeten et al., 
2007; Kiwanuka et al., 2008 and 2009). Despite the up-scale of cART in Cameroon 
since 2003 and other government initiatives like PMTCT programs, there are still 
many reported cases of new HIV-1 infections especially in pediatrics. This has called 
for continual surveillance of HIV-1 subtypes that could be responsible for the spread 
of the virus.  






The specific objectives were;  
1. To characterize and identify new HIV-1 circulating recombinant forms 
2. Analyse drug resistance mutations from naïve and treated, infants/children 
and adults in Yaoundé, Cameroon.  
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Cameroon is located in Central-West Africa, bordered to the South by the Republic of 
Congo, Gabon & Equatorial Guinea, to the West by Nigeria and to the Northeast by 
Chad and East by the Central African Republic. It is a politically stable country with 
approximately 24 million inhabitants (World Development Indicators (WDI), 2015). 
(http://knoema.com/WBWDIGDF2015Aug/world-development-indicators-wdi-
september-2015?tsId=1555540). Yaoundé is the capital city with approximately 2.5 
million inhabitants. The country has a complex cultural, social and geographical 
diversity, with French and English as the official languages (Fonjong, 2001). Our 
study focussed on Cameroon because it harbours a high viral diversity of HIV-1 
subtypes and drug resistance rates in both Central and West Africa (Aghoken et al., 
2013). This study consists of two unrelated groups of therapy naïve HIV-1 positive 
patients; (1) infants/children and (2) adults. From here on, infants/children will be 
assigned as ‘Cohort I’ and adults as ‘Cohort II’. This chapter will focus on cohort I. 
 Ethical statement 
Ethical clearance was obtained from the Cameroon National Ethical committee with 
reference number 049/CNE/SE/2013 (Appendix I) and was reviewed in 2014, 2015, 
2016 and 2017. The study protocol has also been approved by the Health Research 
Ethics Committee at Stellenbosch University with the project reference number 
N14/10/130(Appendix II). The study was conducted according to the ethical 
guidelines and principles of WHO 2015, South African Guidelines for Good Clinical 





Practice and the South African Medical Research Council (MRC) Ethical Guidelines 
for Research. 
 Study Design  
This was a cross sectional study conducted between 2013 and 2017. The study 
participants enrolled at the Chantal Biya Foundation Hospital, the Centre for the 
Study and Control of Communicable Diseases (CSCCD) research institute - based at 
the Faculty of Medicine and Biomedical Sciences (FMBS) of the University of 
Yaoundé I. Other collection sites included District hospitals and other peripheral 
clinics within Yaoundé, Cameroon as shown in Figure 2.1. A summary of sample 
processing and analyses are described in Figure 2.2. 
 
 Figure 2.1 A map showing the different health districts around Yaoundé, Cameroon. 
The samples were obtained from the 5 different health districts, surrounding the 
CSCCD research institute and the University of Yaoundé I, Cameroon. The map was 
created with scribble maps (www.scribblemaps.com) (Ikomey et al., in press).  






Figure 2.2 An illustration of procedures and molecular techniques used for sample 
processing and analyses in the study cohorts. Plasma samples were collected in their 
respective cryovial tubes (step 1) Viral RNA is extracted (step 2). The RNA sample is 
amplified using PCR (thermocycler) (step 3) to obtain a high yield of amplicons and 
converted into cDNA (step 4) in a reverse transcription process. Positive amplicons are 
visualized in agarose gel photo (step 5) and sequenced with consensus sequences in a 
chromatogram window (step 6). A quick analysis of HIV-1 subtypes is done using 
various online programs like REGA and RIP (step 7). HIVDR analysis is performed using 
Stanford drug resistance data base (step 8) and a Neighbor-Joining (NJ)phylogenetic 
tree drawn using MEGA version 5 (step 9) to cluster closely related HIV subtypes. 
 Study participants   
 They consisted of 55 therapy naïve HIV-1 positive infants/children aged 2 weeks – 
72 months old. The infants in this study were under 28 days of age (according to 
WHO, 2017 - http://www.who.int/topics/infant_newborn/en/) while those above this 
age and up-to 18 years were defined as children All protocols for infant/children HIV 
screening were followed according to established consolidated 2015 WHO 
guidelines. The guidelines include: Patient consent (proxy consent for children), 





confidentiality, counselling, correct test results and connection/linkage to prevention, 
treatment and care services.  
 Equipment, chemicals, reagents, commercial assays and enzymes 
A list of equipment (Table 2.1), chemical reagents, commercial assays kits and 
enzymes (Table.2.2), miscellaneous items (Table 2. 3), software packages and HIV-1 
subtype online programs (Table 2. 4) for this study are listed as follows: 
Table 2.1 Equipment used for sample assays and analysis 














Allegra ™ 6R 
centrifuge 
Sample preparation Beckman Coulter California, USA 
Microfuge® 16 Sample preparation Beckman Coulter California, USA 
Vortex Mixer VM 
300 
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genetic analyser  










Table 2.2 Chemical reagents, commercial assay kits and enzymes 
Products Supplier Catalogue 
number 
HIV Determine  Abbott Laboratories, USA 7D2649 
ImmunoComb®  BiSpot, Orgenics 06G00063 v01 
CD4 FACScount reagent Becton Dickinson, Belgium 339010 
ELISA kits, Integral Enzygnost®  Siemens, France DP400 
qRT-PCR AMplicor 1.5 commercial 
viral kit 
Roche diagnostics, USA 236700791 
QiaAmp viral RNA Mini Kit Qiagen, Germany 151017169 
SuperScript® III Taq High Fidelity Invitrogen, Life technologies 12574-030 and 
12574-035 
GoTaq® G2 Flexi DNA Polymerase Promega M7805 
Nuclease free water QIAGEN, Germany 145045078 
SeaKem® LE Agarose WhiteSci/Lonza,  USA 50004 
GRGreen Nucleic Acid Gel Stain Excellgen Ltd., South Africa IV-1071 
6x Blue Orange Loading Dye BioLabs, USA B7022S 
GeneRulerTM 1kb DNA ladder BioLabs, USA    0461505 
QIAquick PCR Purification Kit QIAGEN, Germany 28 106 
BigDyeTM Terminator cycle 
sequence ready Kit 
Applied BioSystems, USA 4 337 035 
5x Sequencing Buffer Applied BioSystems, USA 4 305 603 
BigDye XTerminator Purification Kit Applied BioSystems, USA 4 374 408 
 
 





Table 2.3 Software packages 
Software package References and/or licensed 
companies 
Sequencher version 5 Gene Codes Corporation, USA 
MAFT version 7 http://mafft.cbrc.jp/alignment/server/   
(accessed on 15/04/2017) 
BioEdit version 5.0.9 Hall, 2003. Ibis Biosciences, USA 
MEGA version 5.0 Tamura et al., 2011 
Geneious Biomatters Ltd, New Zealand 
Table 2.4 Databases used for sequence analysis 
Web Address                                                 Databases 
Los Alamos National Laboratory HIV 
Sequence Database  
http://www.hiv.lanl.gov 
(accessed10/11/2016) 
Stanford University- HIV Drug 
Resistance Database version 8.4  
https://hivdb.stanford.edu/hivdb/by-
mutations/  (accessed on 22/03/2017) 
Los Alamos National Laboratory HIV 
Sequence Database- Quality Control  
http://www.hiv.lanl.gov/content/sequen
ce/QC/index.html (accessed on 
22/11/2016) 
Context-based Modeling for 
Expeditious Typing (COMET)  
https://comet.lih.lu/ (accessed on 
06/10/2016) 




(accessed on 08/11/2016 
 Subtype classification using 
evolutionary algorithms (SCUEAL) 
http://www.datamonkey.org/datauploa
d_scueal.php (accessed on 
03/02/2017 
jumping profile Hidden Markov Models 
(jpHMM) 
http://jphmm.gobics.de (accessed on 
12/02/2017 
Recombinant Identification Program 
version 3 (RIP 3.0) 
http://www.hiv.lanl.gov/content/sequen
ce/RIP/RIP.html (accessed on 
18/02/2017 





Table 2.5 Miscellaneous items 
Item  Supplying Company 
Laboratory wear Labotec, South Africa 
1x TAE buffer BioLabs, USA 
Glassware Labotec, South Africa 
Laboratory liquids (Ethanol, Methanol) Sigma-Aldrich, USA 
Parafilm Sigma-Aldrich, USA 
Pipettes Thermo Fisher Scientific, South Africa 
Pipette tips Thermo Fisher Scientific, South Africa 
Sterile filters and filter papers Thermo Fisher Scientific, South Africa 
BD vacutainer® tubes BD Biosciences, USA 
Plastic material Thermo Fisher Scientific, South Africa 
 Sample collection, preparation and storage 
Study participants who consented / proxy-consented (for infants / children), 
completed a case record form. Briefly, 3-5 mL of whole blood from 55 therapy naïve 
infants / children, were drawn into Ethylene diamine tetra-acetic acid (EDTA) Becton, 
Dickinson (BD) Vacutainer® collection tubes (BD Biosciences, USA) using standard 
phlebotomy collection procedures. The blood samples were anonymized and given a 
unique study number. Plasma samples were separated by centrifuging the 
anticoagulated EDTA whole blood at 2000 revolution per minute (rpm) for 10 minutes 
at 18-25°C room temperature using a Microfuge® 16 centrifuge (Beckman Inc, USA). 
The collected plasma sample was aliquoted into two separate 5 mL cryogenic vials 





(Rotest, China) with one tube of plasma kept at -20°C for serological testing and viral 
load screening at the CSCCD laboratory. The other plasma sample tubes were safely 
packaged under -20°C conditions and shipped to the Division of Medical Virology, 
Tygerberg Academic Hospital - Stellenbosch University, South Africa for diversity 
studies and drug resistance testing.   
 HIV testing 
HIV Serology status were confirmed based on the Cameroon national algorithms 
which involves the use of two HIV rapid diagnostic test and a confirmation with an 
antigen p24 antibody detection ELISA kits. The Alere Determine™ HIV–1/2, (Abbott 
Laboratories, USA) and the SD Bioline HIV 1/2 version 3.0 (Standard Diagnostics, 
Inc.) were used with an ELISA antigen antibody kit (Integral Enzynost ELISA kits, 
Siemens, France). All tests were carried out following the manufacturer’s guidelines. 
 Determination of Cluster of differentiation 4 Thymus-cell counts and 
percentages 
The CD4 cell counts was done using standard methods following manufacturer’s 
instructions. 
Principle: The FACS count system consists of a pair of reagent tubes containing 
fluorochrome-conjugated monoclonal antibodies and reference beads for calculation 
of absolute lymphocyte values. The system is designed to use EDTA anticoagulated 
whole blood. When whole blood is added into FACS count reagent tube, the 
antibodies bind specifically to lymphocyte cell surface antigens forming a 
cluster/population of cells. These cluster cells fluoresce different colors and the BD 





FACS count machine detects two colors and measures the relative size of the cell. 
The cluster CD4+ and CD8+ T-cells fluorescence yellow, while CD3+ cells fluoresce 
red colour. Five percent (5%) formaldehyde fixative is added to the sample/reagent 
mixture for sample stability and as a biohazard protection. Using an internal software 
algorithm (FACS count Software v 1.0, 4/93), the BD FACS count instrument 
enumerates the absolute values of the CD4+, CD8+ and CD3+ cell count.  
 
Figure 2.3 A graphic representation of the Becton Dickinson FACS count 
software algorithm evaluating cluster of CD4+ T-cells with reference beads using 
an elliptical orbit region that localizes on the center of each population. Sufficient 










Method: Fifty-five microLitre (50µL) of Whole blood collected in EDTA tubes were 
used for CD4 absolute and percentages counts. This was based on the principle of 
immunophenotyping using an automated Fluorescence Activated Cell Sorting (FACS) 
Count Analyzer using the Becton Dickinson (BD) FACSCount trio CD4/CD8/CD3 
reagent kit (BD Biosciences, USA). Samples were analysed based on the 
manufacturers’ guidelines including the quality controls as illustrated in Figure 2.3 
and previous studies (Ikomey et al., 2016). 
 RNA extraction 
HIV RNA was extracted from plasma samples using the QIAamp Viral RNA Mini Kit 
(Qiagen, Germany) (Figure 2.3).  
Principle: The QIAamp Viral RNA Mini procedure extracts all RNA molecules larger 
than 200 nucleotides. The sample is first lysed under highly denaturing conditions to 
inactivate RNases and to ensure isolation of intact viral RNA. Buffering conditions are 
adjusted to provide optimum binding of the RNA to the QIAamp membrane and the 
sample is loaded onto the QIAamp Mini spin column. The RNA binds to the 
membrane and contaminants are efficiently washed away in two steps using two 
different wash buffers. High-quality RNA is eluted in a special RNase-free buffer, 
ready for direct use or safe storage. The purified RNA is free of protein, nucleases 
and other contaminants and inhibitors.  
Method: Working under a biosafety cabinet (HR60-IIA2, United Scientific (PTY) Ltd, 
South Africa), we added 140μL of equilibrated plasma into 560μL of prepared viral 
lysis buffer (Buffer AVL) containing carrier RNA into a 1.5mL microcentrifuge tube 





(ThermoFisher, USA). Complete sample lysis was achieved by pulse-vortexing the 
mixture using the Vortex Mixer VM 300 (Gemmy Industrial Corp, Taiwan), followed by 
a 5 minutes incubation period at room temperature. The lysed sample was pipetted 
into the QIAamp mini column so that the viral RNA could bind onto the QIAamp mini 
column membrane. This was followed by two wash rounds with prepared wash buffer 
1 (buffer AW1) and wash buffer 2 (buffer AW2) to remove contaminants that would 
otherwise lower the purity of the RNA elute. Pure RNA was eluted using RNase free 
Viral Elution buffer (buffer AVE). Centrifugation was done using the Microfuge® 16 
(Beckman Inc, California, USA) and all protocols strictly observed the manufacturer’s 
instructions to avoid any contamination. 
 Viral load screening 
The quantitative qRT-PCR Amplicor1.5 commercial viral load kit was used to 
determine HIV-1 viral load Test (Roche Diagnostic Systems, USA). The assay was 
performed with a prepared master mix containing oligonucleotide primers specific to 
regions of the HIV-1 gag gene with upstream sense primers of Sk145 (1359 – 1388 
in HXB2 gene map location) - 5’-ACTGGGGGGACATCAACCACCCATGCAAT-3′ 
and the downstream antisense of SKCC1B (1486-1513 in HXB2 gene map location) -  
5’-TACTAGTAGTTCCTGCTATGTCACTTCC-3’. The limit of detection of the assay 
was 67log10 or less than 40 copies /mL. 
 RNA concentration and quality estimation  
This was done to detect the presence of other proteins or contaminants/co-purified 
contaminants. It also helped us to determine the right amount of RNA sample to use 





for our downstream procedures. We used 1µL of RNA sample to determine RNA 
concentration and quality spectrophotometrically in ng/µL using the NanoDrop® ND-
1000 V3.1.0 (Nanodrop Technologies Inc, USA). As per the manufacturer’s 
instructions, RNA absorbance was measured at a wavelength of 260nm to determine 
the RNA concentration. RNA purity was determined by a ratio of sample absorbance 
at 260nm and 280nm with accepted RNA purity at approximate ratio of 2.0. Any RNA 
sample of a ratio 1.8 to 2.2 was generally accepted as of good quality and hence 
forth used for our next procedure. 
 Location of genome of interest 
For HIV-1 molecular characterization and detection of RAMs, we used PR, RT and IN 
fragments of the HIV-1 pol gene. The pol gene location is in relation to HXB2 gene 
map below Figure 2.4. 
 
Figure 2.4 HXB2 gene map showing the pol genome (colored blue) – available at:  
http://www.bioafrica.net/proteomics/POLprot.html.The partial pol gene (PR) at HXB2 
location 2136 – 2650 for PR; 2530 – 3334 for RT and 4470 – 4806 for IN were 
amplified and sequenced for genotypic typing and drug resistance testing. 
 Primers for PCR amplification 
Primers for PR and RT amplification were used as previously described (Plantier et 
al., 2005; Jacobs et al., 2008). Primers for the PR fragment are indicated in Table 2.6 





and primers for the RT fragment are indicated in Table 2.7; Primers for Integrase (IN) 
as described (Miura et al., 1990) are indicated in Table 2.8. Annealing temperatures 
for all primers are also given.  
Table 2.6 PR Fragment amplification primers 
 




































































Table 2.8 IN fragment amplification primers 
 Polymerase Chain Reaction  
Polymerase chain reaction (PCR) was done in two reactions – Pre-nested and 
Nested PCR. In the pre-nested PCR, the targeted RNA fragment was reverse 
transcribed to cDNA. This was followed with amplification of the cDNA to dsDNA 
amplicons using gene specific primers and SuperScript® III (SSIII) One-Step 
Reverse Transcriptase-PCR System with Platinum® Taq High Fidelity enzyme 
protocol (Invitrogen, USA). According to the manufacturer’s instructions, the SSIII - 
RT system detects RNA targets from 300bp to 10kb and very little amount of RNA 
ranging from 1pg to 1µg can be used. The second PCR reaction (Nested PCR) 
involved amplifying the DNA PCR products from the first PCR assay using gene 
specific primers and GoTaq® G2 Flexi DNA Polymerase Protocol (Promega, USA). 
The GoTaq® assay kit amplifies a wide range of PCR fragments, consistently 
producing high amplicon yields that are highly reliable. The target PCR amplification 
Primers Annealing 
Temperature 

































products for each fragment were 514bp, 804bp and 336bp for PR, RT and IN 
respectively. 
Principle: A PCR amplification assay operates under optimally set temperature 
conditions and cycles to obtain a successful yield. Three major concurrent steps 
consisting of heat denaturation, primer annealing to the template and elongation of 
the target RNA/DNA fragment are involved. The PCR amplifies exponentially and 
expected target copy numbers is given by the formula; 2n, where n = number of PCR 
cycles and the resultant copies range in billions. 
2.14.1 Pre-nested RT- PCR 
This PCR reaction targeted HXB2 location 2082 – 2734 (652bp) for the PR fragment 
while 2480 – 3420 (940bp) and 4025 – 4978 (953bp) were targeted for the RT and IN 
fragments respectively. To obtain the PCR pre-nested products, the SSIII kit protocol 
(Invitrogen, USA) was used for initial amplification for all 3 HIV-1 pol fragments (PR, 
RT and IN). Specific outer target primers with their specific annealing temperatures 
used are indicated above in Table 2.6 for PR, Table 2.7 for RT and Table 2.8 for IN 
fragments. The RNA was first reverse transcribed to cDNA using following 
manufacturer’s instructions. All PCR amplification steps were done using the 
GeneAmp PCR System 9700 thermal cycle (Applied Biosystems, USA). Briefly, a 
master mix of a 50µL reaction volume (shown in Table 2.9) was prepared as follows: 
25 µL of 2x reaction mix buffer was added with 1 µL of 10µM specific forward primer 
and 1µL of 10µM specific reverse primer (as indicated above in Table 2.6, 2.7 and 
2.8), 1µL of SSIII enzyme mix, 5 µL of 1pg -1µg total RNA and Nuclease free water  





(QIAGEN GmbH, Germany) filling up to the 50 volume in a 0.2 mL thin-walled PCR 
tube. We used a standard protocol of PCR amplification as indicated in the Table 
2.10. 
Table 2.9 A master mix for pre-nested PCR in a 50 µL reaction volume reaction 
Component Volume 
2x reaction Mix 25 µL 
Outer/Forward primer,10 µM as indicated above in Table 5 for PR, 
Table 6 for RT and Table 7 for IN fragments 
1 µL (0.5mg/µL) 
Outer/Reverse primer,10µM as indicated above in Table 5 for PR, 
Table 6 for RT and Table 7 for IN fragments 
1 µL (0.5mg/µL) 
SuperScript® III RT/Platinum® Taq High Fidelity Enzyme Mix 1 µL 
Template RNA (1 pg- 1 µg) 5 µL 
Nuclease Free water 17 µL 
Total 50 µL 
Table 2.10 Cycling conditions for Pre-nested PCR 
Step Temperature Time Hold/Cycle 
Initialization and cDNA synthesis 500C 30 minutes 
1 hold 
pre-denaturation 940C 2 minutes 
Denaturation 940C 15 seconds 
40 cycles Primer annealing 55
0C for PR and RT 
500C for IN 
30 seconds 
Extension 680C 1 minute/kb 
Final extension 680C 5 minutes 1 hold 
Product was Cooled and stored at 40C until used 





2.14.2 Nested PCR 
This was the second PCR reaction using GoTaq® G2 Flexi DNA Polymerase 
Protocol (Promega, USA). The PCR products amplified was 2136 -2650 (514bp), 
2530 – 3334 (804bp) and 4470 – 4806 (336bp) in HXB2 location for PR, RT and IN 
respectively. All the nested PCR steps were done using the GeneAmp PCR System 
9700 thermal cycle (Applied Biosystems, USA). Briefly, a master mix of a 50µL 
reaction volume as shown in Table 2.11 was prepared as follows; 10 µL of 5x 
GoTaq® Flexi buffer1 was added into 4µL of 25mM MgCl2 Solution, 1μL of 
dinucleotide Triphosphates (dNTPs) mix (10mM each), 1μL of 0.1-1.0μM 
inner/forward primer and 1μL of 0.1-1.0μM inner/reverse primer (as indicated above 
in Table 2.6, 2.7 and 2.8), 0.5μL of 5u/μL GoTaq® Flexi DNA Polymerase, 5μL of 
DNA template and nuclease free water filling the required 50 volume in a 0.2 mL thin-
walled PCR tube. A standard protocol for cycling conditions was used as indicated in 
Table 2.12. 
Table 2.11 A master mix for Nested PCR (PR fragment) in a 50 reaction volume 
Component Volume 
5X colorless GoTaq® Flexi Buffer1 10 µL 
MgCl2 Solution, 25mM1 4 µL 
PCR Nucleotide Mix (dNTPs), 10mM each 1µL 
Inner/forward primer (10 µM) as indicated above in Table 5  
for PR, Table 6 for RT and Table 7 for IN fragments 
1µL(0.5mg/µL) 
Inner/Reverse primer (10 µM) as indicated above in Table 5 for PR,  
Table 6 for RT and Table 7 for IN fragments 
1µL(0.5mg/µL) 
GoTaq® G2 Flexi DNA Polymerase (5U/µL) 0.5 µL 
Template DNA(cDNA) 5µL 





Table 2.12 Cycling conditions for nested PCR  
Step Temperature Time Hold/Cycle 
Initialization 950C 2 minutes  1 hold 
Denaturation 950C 1 minute  
30 cycles 
Primer annealing 600C for PR and RT 
500C for IN 
 
1 minute 
Extension 720C 1 minute/kb of DNA 
Final extension 720C 5 minutes 1 hold 
Cooling and storage at 40C until used 
2.14.3 Visualization of the nested PCR amplicons 
Agarose gel electrophoresis was used to separate and identify the nested PCR 
amplicons.  
Principle: Agarose gel electrophoresis separates macromolecules such as DNA by 
size (length in base pairs) in a matrix of agarose under an electric field with a 
constant voltage and a predetermined time for optimal results. The macromolecules 
move from a negative to a positive electrode separating the samples (Sambrook et 
al., 2001; Yilmaz et al., 2012). 
Method: The gel was prepared according to the method described by Sambrook et 
al., 2012 as follows; one gram of agarose powder (Seakem LE® agarose: FMC 
Bioproducts, USA) was dissolved in 100mL of 1x Tris Acetate EDTA (TAE) buffer to 
obtain a 1% weight per volume (w/v) agarose gel concentration. The melted agarose 
was cooled to 550C and 10μL of GRGreen gel stain (Excellgen Ltd, South Africa) was 





added before the gel was cast onto a tray measuring 7 x 10 cm. Three microliter 
(3µL) of PCR product was mixed well with 5μL of Orange (6X) gel loading dye (2.5% 
Ficoll and 0.15% Orange (6X) (BioLabs, USA) and loaded into sample wells with 
positive and negative controls. The GeneRulerTM1kb DNA ladder (Promega, USA) 
was used as a molecular weight marker. The gel ran at 75 Volts for approximately 45 
minutes and was visualized under ultra violet (UV) light with a wavelength of between 
254nm-365nm using the UVItec gel documentation system (Cambridge, United 
Kingdom). Expected positive bands of fragment size 514bp for PR, 804bp for RT and 
336bp for IN were identified, photographed and the corresponding PCR products 
used for purification and sequencing. 
2.14.4 Purification of PCR products  
The QIAquick PCR purification kit (Qiagen, Germany) was used to purify the PCR 
products as per the manufacturer’s instructions.  
Principle: Nucleic acids binds to the QIAquick spin column membrane under 
buffering conditions (10 mM Tris·Cl, pH 8.5) and impurities are washed down through 
centrifugation at 8000 revolutions for 10 minutes (Sambrook et al., 2001). This is 
followed by elution of purified RNA under the same buffering conditions and an 
aliquot of the purified RNA product is obtained and stored at -200C to prevent any 
contamination especially through RNase activity. 
Method: PCR amplified products (double stranded DNA) were purified from excess 
primers, enzymes, nucleotides, polymerases and salts used during PCR amplification 





and gel separation. The eluted purified DNA was kept at -200C for the next 
procedure, to prevent degradation. 
 DNA sequencing 
DNA sequencing was developed by Fredrick Sanger and colleagues in 1977 (Sanger 
et al., 1977). It determines the order of the four bases - ATCG in the targeted DNA 
sample through a capillary process. 
Principle: The sequencing method is based on selective chain-termination of 
modified dideoxynucleoside triphosphate (ddNTPs) in an enzymatic reaction. The 
four dNTPs are enzymatically added by the DNA polymerase forming a long chain of 
DNA fragment. Once the DNA fragment is formed, the fluorescently labelled ddNTPs 
terminate the reaction. This is because the ddNTPs lack 3’- OH group which is 
necessary for the formation of a phosphodiester bond between two nucleotides. The 
results are interpreted by the genetic analyzer software by calling the bases at each 
data point depending on the intensity of emitted fluorescence from the ddNTPs. 
Method: A master mix of 10μL reaction volume was prepared as follows; 2μL of DNA 
template was added into 1μL of BigDyeTM X Terminator (Applied Biosystems, USA) 
Enzyme mix, 2μL of 5x sequence buffer, 1μL of each primer (Table 2. 13) and 4μL of 
nuclease free water to fill-up the required volume in a 0.2mL thin-walled sequencing 
tube. The reaction cycle was run as described below in Table 2.14. The products 
were purified using the BigDyeTM XTerminator Cycle Sequencing Ready Reaction Kit 
and analysed using the automated ABI 3130xl genetic analyser (Applied Biosystems, 
USA).  





Table 2.13 Sequencing primers 
PR Primers Annealing 
Temperature 
Oligonucleotide sequence  
















2136-2163 Plantier et 
al., 2005 
























3310-3334 Plantier et 
al., 2005 
IN primers     
Poli 3 55°C TAGTGGGATGTGTACTTCTG
AAC 
5195-5217 Miura et 
al.,1990 
Poli 4 55°C CACACAAAGGRATTGGAGG
AAATG 
4162-4185 Miura et al., 
1990 





Table 2.14 Sequence PCR cycling parameters 
Step Temperature Time Number of cycles 
Pre-denaturation 960C 1 minute 1 
Denaturation 960C 10 seconds 
25 Primer Annealing 55
0C 7 seconds 
Elongation 600C 4 minutes 
Cooling and storage at 40C until used 
2.15.1 Quality control of DNA sequences  
Quality DNA sequences obtained were checked to exclude contamination, detection 
of phylogenetic signal and recombinants in HIV-1 using the Los Alamos sequence 
database (http://www.hiv.lanl.gov/content/sequence/QC//index.html). 
2.15.2 Multiple sequence alignment 
Sequence alignment allows for all homogenous nucleotide sequences to be 
compared and aligned. The sequence alignment uses a heuristic approach whereby 
sequences are aligned progressively following a guide tree (Feng & Doolittle, 1987). 
In this study, sequences were checked for presence of multiple stop codons, 
frameshifts and hypermutations before aligning them. Multiple alignments of 
nucleotides were aligned using MAFFT version 7 
(http://mafft.cbrc.jp/alignment/server/). 
 





 HIV-1 subtyping using online programs 
A variety of online HIV-1 programs were used for preliminary HIV-1 subtype and 
recombinant characterization. These were, Recombinant Identification Program 
version 3 (RIP 3.0) (http://www.hiv.lanl.gov/content/sequence/RIP/RIP.html; Holguin 
et al., 2008), REGA HIV Subtyping Tool version 2 
(http://www.bioafrica.mrc.ac.za/rega-genotype/html/subtypinghiv.html); Alcantara et 
al., 2009), Subtype classification using evolutionary algorithms (SCUEAL) 
(http://www.datamonkey.org/dataupload_scueal.php); Delport et al., 2010), Context-
based Modeling for Expeditious Typing (COMET) 
(http://www.comet.retrovirology.lu;Struck et al., 2014) and the jumping profile Hidden 
Markov Models (jpHMM) webserver (http://www.jphmm.gobics.de); Schultz et al., 
2009; Bulla et al., 2012).  
 Drug resistance analyses 
RAMs analyses was performed using the Stanford HIV drug resistance data base 
(HIVDB) version 8.4 algorithm, available at http://hivdb.stanford.edu. The HIVDB was 
preferred because it mostly targets genotypic data from the pol genome (PR, RT and 
IN). The data collected can then be easily correlated with treatments of individuals 
through genotypic drug resistance assays. The Stanford HIVDR is easily accessible 
through HIVDB data base and is continuously updated to reflect emerging RAMs 
against FDA approved antiretroviral drugs (Kantor et al., 2001; Shafer, 2006; Wang 
et al., 2007). 
 





 Phylogenetic inference 
Information from DNA sequences is converted into evolutionary trees using molecular 
phylogenetic analyses (inference). The topology of the tree is based on similarities 
and/or differences between the DNA sequences. Thus, the more closely they appear 
the more similar they are. As the HIV-1 evolves rapidly, a phylogenetic tree is better 
placed to give detailed information, especially on viral origin, diversity and spread, 
which is important in managing the HIV-1 pandemic. To make the best estimate of 
the evolutionary history that is based on the inheritance of ancestral characteristics of 
DNA sequences obtained from HIV-1, a phylogenetic inference was used based on 
the inheritance of ancestral characteristics. In this study cohort, a Neighbor-Joining 
(NJ) phylogenetic tree was inferred using MEGA version 5.0 (Tamura et al., 2011) as 
follows – the contigs obtained from chromatograms were assembled using 
Sequencher version 5 (Gene Codes Corporation, USA) and HXB2 sequence was 
used as a reference. Sequence contigs were obtained and edited using BioEdit 
version 5.0.9 (Ibis Biosciences, USA). Multiple sequence alignments (MSA) of 
sample nucleotide sequences were created using MAFFT version 7 
(http://mafft.cbrc.jp/alignment/server/). Gaps were removed from the final alignment 
before performing a phylogenetic inference. A jModelTest was used to determine the 
“best model” for phylogenetic tree reconstruction. This was done by loading the 
MAFFT aligned DNA sequences file unto the jModelTest folder and analysis done by 
computing likelihoods. The “best model” determined for this study was the TIM1+G 
model (with 012230 partition and 0.2820 gamma distribution) that was selected under 
the Bayesian Information Criterion (BIC). The MEGA version 5.0 that was used for 





phylogenetic analysis does not have the TIM1+ G model so the closest model with 
similar parameters was Tamura 3 model (T92) was selected. Reliability of the 
branching order of the phylogenetic trees was tested using bootstrapping analyses of 
1000 replicates for all datasets. 
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This section describes the social-demographics (gender and age) and clinical data of 
the 55 study participants in this cohort as tabulated in Table 3.1. The clinical data 
includes the CD4 and viral load measurements that were taken as part of the 
diagnostic assays. Amplification and sequencing was successful in 29/55 (52.7%), 
27/55 (49.1%) and 28/55 (50.9%) for PR, RT and IN fragments as summarized in 
Table 3.2.  
 Social-demographics and clinical data 
Fifty-five infants/children were recruited for the study [32 (58.0%) females and 23 
(42.0%) males]; with an age range of 9 months to 6 years and a mean age of 2.5 
years old. CD4 percentages and absolute counts ranged between 30.0% and 44.0% 
(median 33.0%, 500-2000 cells/m3, with a mean of 957). HIV-1 plasma RNA viral 
loads ranged between 4.6 and 5.87 log10 copies per milliliter (median 4.96). The 
social-demographic information and clinical data are summarized in Table 3.1.  




























Naïve ART Pregnant mothers 







 Mean Range 
Age (Years) 2.5 0.8 – 6 
CD4 Count (absolute) 958 500 – 2000 
CD4 (%) 36 15 – 44 
Viral Load (log10) 4.40 4.6 – 5.9 
 Viral RNA amplicons 
Viral RNA was extracted from all the 55 plasma samples with RNA concentration in 
ng/µL ranging between 35-120 ng/µL and purity levels between 1.70 and 2.0. Above 
10 ng/µL and purity from 1.8 - 2.0 was required for successful downstream 
procedures, which was obtained from all of the 55 samples. 





 Detection of PCR amplicons (PR, RT and IN)  
PCR amplification of the 3 fragments of the pol gene (PR, RT and IN) were done on 
all 55 viral RNA extracted samples. The samples were amplified in 2 runs (first and 
second) and positive bands were visualized on 1.0% TAE agarose gel picture as 
shown in examples in Figure 3.1, 3.2 and 3.3 for PR, RT and IN; respectively. 
 
Figure 3.1 Partial pol (PR) fragment of 507 bp length in 1.0% TAE agarose gel picture. 
An example of positively amplified samples that include number, 45, 39, 52 and 57. 
Samples number, SubO, 38, 35, 37 and 22 are examples that could not be amplified 
with available PR primers. One kilo-base (1kb) DNA ladder at both ends of the gel 
picture - showing different bands of corresponding DNA concentration in nanograms 
(ng), was used as DNA marker (DM). MJ4 plasmid positive control (PC) and Non-
template control (NTC) were included as controls. The gel was stained with GRGreen 
Nucleic Acid Gel Stain (Excellgen Ltd., South Africa). 






Figure 3.2 Partial pol (RT) fragment of 804 bp length in 1.0% TAE agarose gel picture. 
An example of positively amplified samples that include numbers, 1, 3-5, 7-10, 12-16 
and 18 is indicated, while examples of samples 2, 6, 11, 17 and 19 would not be 
amplified with available RT primers. One kilo-base (1kb) DNA ladder at both ends of 
the gel picture - showing different bands of corresponding DNA concentration in 
nanograms (ng), was used as DNA marker (DM). MJ4 plasmid positive control (PC) 
and Non-template control (NTC) were included as controls. The gel was stained with 
GRGreen Nucleic Acid Gel Stain. 
 
Figure 3.3 Partial pol IN fragment of 306 bp length in 1.0% TAE agarose gel picture. 
An example of positively amplified samples that include numbers, 510, 10, 22, 
57,29,14,01 and 02, while an example of samples 35,19,17,16 would not be 
amplified with available IN primers. One kilo-base (1kb) DNA ladder at both ends of 
the gel picture - showing different bands of corresponding DNA concentration in 
nanograms (ng), was used as DNA marker (DM). MJ4 plasmid positive control (PC) 
and Non-template control (NTC) were included as controls. The gel was stained with 
GRGreen Nucleic Acid Gel Stain. 





From the 55 samples, 29/55 (52.7%) PR amplicons were amplified, while 27/55 
(49.1%) and 28/55 (50.9%) amplicons were amplified for RT and IN; respectively 
(Table 3.2 section A). A total of 37/55 (67.3%) amplicons were amplified for at least 
one of the pol gene fragments (PR or RT or IN) (Table 3.2 section A). Eighteen out of 
55 samples (32.7%) amplifications were successful across all the 3 fragments; while, 
23/55 (41.8%), 22/55 (40.0%) and 19/55 (34.0%) were amplified for PR/RT, PR/IN 
and RT/IN, respectively. A summary of all amplifications is provided in Table 3.2. 
Table 3.2 Summary of positively amplified pol gene fragments 




PR 29 52.7% 
RT 27 49.1% 
IN 28 50.9% 
Either PR or RT or IN amplified 37 67.3% 
 Two or 3 fragments amplified per sample 
B 
Samples amplified in all of the 3 
fragments (PR, RT and IN) 
18 32.7% 
PR and RT 23 41.8% 
PR and IN 22 40% 
RT and IN 19 34% 
 Sequencing  
All PCR amplicons for the three pol fragments (PR, RT and IN) were sequenced on 
both strands with forward and reverse primers mentioned under materials and 
methods in section 2.9 (Table 2.12). Typical sequence clean data chromatogram was 





obtained as shown in example of sample CM-014 (Figure 3.4). The Sequencher 
parameters were customized to a 3’ gap placement with a minimum overlap of 20 
and a minimum match of 75.0%.  
 
Figure 3.4 An example of a clean chromatogram from sample CM-014 with clearly 
defined peaks. The peaks in different colour sheds of green, red, blue and black 
represent adenine, thymidine, cytosine and guanosine nucleotides; respectively. The 
size of the nucleotide peak corresponds to its concentration. 
 Sequence alignment  
After a quick screening of HIV-1 subtypes in all amplified pol gene products using 
online programmes, an assembly of overlapping sets of nucleotide sequences of 
different reads was run using MAFFT v7 ( http://mafft.cbrc.jp/alignment/server/).This 
was only possible in RT fragment of 23 samples that included: CM-03, CM-05, CM-
08, CM-09, CM-013, CM-014, CM-16, CM-017, CM-17, CM-19, CM-021, CM-21,CM-
24, CM-29, CM-30,CM-31, CM-33, CM-39, CM-44, CM-47,CM-57, CM-177 and CM-
510. These 23 samples had >400 nucleotide sequences in length enabling a quality 
and reliable tree to be drawn. The other two pol fragments (PR and IN) and 4 RT 





samples had majority of sequences being <300 nucleotides due to lack of 
appropriate primers for better amplification. HIV reference sequences used to align 
sample sequences were retrieved from Los Alamos National Library. Similar 
nucleotides for both reference and sample sequence in the MAFFT window are 
identified in the same column, and any dissimilarity observed like “g” for “t” or “c” for 
“t” is assumed to be a mutation that can result in change of HIV subtype (Figure 3.5). 
 
Figure 3.5 Nucleotide sequences of RT fragment from 14 samples (CM-16, CM-
44, CM-03, CM-33, CM-47, CM-017, CM-08, CM-05, CM-016, CM-510, CM-31, 
CM-29, CM-17 and CM-24) aligned with HXB2 reference sequences using MAFT 
window. In the first column, a “t” nucleotide has replaced a “c” nucleotide, an 
indicator of a mutation. 





 Preliminary HIV-1 subtyping using various online programmes 
HIV-1 subtyping analysis was interpreted using various online programs that 
included, jPHMM, RIP, REGA, SQUEAL, COMET and Stanford University HIV Drug 
Resistance Database. These online programs provided a quick HIV-1 subtype 
analyses of sample sequences before confirming through phylogenetic inference. An 
example below shows RT sequence of sample (CM-21) classified by REGA, jPHMM 
and RIP online programs (Figure 3.6, 3.7 and 3.8). The location of the sequence in 
HIV-1 gene map was based on the HXB2 reference sequences. The other subtyping 
tools – SCUEAL, COMET and Stanford only gives subtypes with no HIV-1 map 
location. 
3.6.1 Jumping profile Hidden Markov Model (jpHMM) 
The jpHMM subtyping program characterized 100.0% of the sequenced pol 
fragments (PR-29, RT- 27 and IN-28). The subtype results for all the three fragments 
for each sample sequence are shown in Table 3.4, 3.5 and 3.6 for PR, RT and IN 
respectively. An example of subtype inference for patient CM-21 based on RT 
fragment is subtyped as A1 using jpHMM is shown in Figure 3.6 below. 






Figure 3.6 An example of sample sequence (CM-21) subtyped as HIV-1 subtype A1 
(colored red in the pol genome) using jpHMM online subtyping program. The HIV-1 
gene map was based on HXB2 reference. 
3.6.2 Recombinant Identification Program (RIP) 
The RIP subtyping tool characterized 20/29 (69.0%) for the PR and 26/27 (96.3%) for 
RT fragments but would not infer any subtype in all 28 sample sequences of the IN 
fragment. There were no recombinants detected. The RIP characterized sample CM-
013 as subtype G and D for RT and IN, respectively while on the PR fragment it was 
unknown. An example of subtype inference for patient CM-21 based on RT fragment 
is subtyped as A1 using this online program and is shown in Figure 3.7 below. 






Figure 3.7 Sample CM_21 screened rapidly for inter-subtype recombination using RIP 
online program. The background contains consensus and subtype reference 
sequences of HIV-1 subtypes with subtype A1 (in red line) being the closest to the 
sample sequence. 
3.6.3 REGA version 3.0 
The REGA version 3.0 subtyping Programme characterized 8/29(27.6%), 
13/27(48.0%) and 20/28(71.0%) of sequenced PR, RT and IN samples, respectively. 
In sample CM-013, it only characterized the IN fragment as subtype A1, while the PR 
and RT were unknown. An example of patient CM-21 based on RT fragment was 
inferred as subtype A1 as shown in Figure 3.8 below.  






Figure 3.8 An example of sample sequence (CM-21) of 609 bps in length subtyped as 
HIV-1 subtype A1 (colored red in the pol genome) using REGA online subtyping 
program. The bootstrap is 98.0% which confirms the sample sequence as closely 
related to A1 subtype. The HIV-1 gene map was based on HXB2 reference.  
3.6.4 SCUEAL (DataMonkey Program) 
The DataMonkey subtyping program characterized all 27 and 28 sample sequences 
for RT and IN, respectively; while 26/29 (89.7%) were characterized for PR fragment 
with two remaining unknown. In sample CM-013, it was characterized as subtype 
CRF37, G and CRF19 for PR, RT and IN, respectively. 
3.6.5 Context-based Modeling for Expeditious Typing Program (COMET)  
This program characterized all 29, 27 and 28 sample sequences for PR, RT and IN 
respectively. In sample CM-013, it was characterized as FI, D and A1 for PR, RT and 
IN, respectively. 





3.6.6 Stanford University HIV Drug Resistance Database 
All sample sequences were characterized. Sample CM-013 was characterized as 
CRF02_AG, G and D for PR, RT and IN, respectively. 
Table 3.3 Summary of HIV-1 subtype analyses based on pol (PR) fragment using six 
different online programmes 
Sample HIV subtype analyses 
 jPHMM COMET SCUEAL REGA RIP Stanford 
CM-02 G G CRF37 Unknown Unknown G 
CM-03 
CRF01_AE 
/F1 CRF02_AG CRF02_AG Unknown Unknown CRF02_AG 
CM-05 G CRF02_AG CPX G Unknown CRF02_AG 
CM-08 CRF01_AE CRF02_AG CPX Unknown Unknown CRF02_AG 
CM-09 F2 F2 F2 Unknown F2 F 
CM-011 G G G G G CRF02_2 
CM-013 A1 FI CRF37 Unknown G CRF02_AG 
CM-014 C C C C C C 
CM-016 A1G CRF02_AG CPX Unknown G CRF02_AG 
CM-16 G CRF02_AG G Unknown G CRF02_AG 
CM-017 A1 CRF02_AG G Unknown A1 CRF02_AG 
CM-17 CRF01_AE CRF02_AG CRF37 Unknown CRF01_AE CRF02_AG 
CM-19 C C C C C C 
CM-20 G C 
CRF01_AE / 
G Unknown Unknown CRF02_AG 
CM-21 C C C C C C 
CM-24 G CRF02_AG CRF02 Unknown G CRF02_AG 





Sample jPHMM COMET SCUEAL REGA RIP Stanford 
CM-30 A1 A1 CRF22 A(A1) Unknown CRF01_AE 
CM-31 A1 CRF02_AG G Unknown G CRF02_AG 
CM-32 A1 A1 AE Unknown CRF01_AE K 
CM-33 A1 CRF02_AG CRF37 Unknown G CRF02_AG 
CM-39 CRF01_AE 01AE AE Unknown CRF01_AE K 
CM-44 A1 CRF02_AG A4 / G. Unknown G CRF02_AG 
CM-45 C C C C C C 
CM-47 01_AE / G CRF02_AG CPX Unknown Unknown CRF02_AG 
CM-48 F1 CRF02_AG A2 / G Unknown Unknown CRF02_AG 
CM-52 G CRF02_AG G Unknown G CRF02_AG 
CM-57 A1 A1 CRF22 A(A1) CRF01_AE CRF01_AE 
CM-177 CRF01_AE A1 NONE Unknown Unknown CRF01_AE 
*CM-013 is an example of a sequence that had the PR and IN fragments subtyped as 
subtype A1 while in RT fragment it was subtyped as B/G by jPHMM subtyping 
program 
*Unknown:  the relevant subtyping program was not able to characterize the 
sequence 
Table 3.4 Summary of HIV-1 subtype analyses based on pol (RT) fragment using six 
different online programmes 
Sample jPHMM COMET SCUEAL REGA RIP Stanford 
CM-02 G G G G G G 
CM-03 CRF01_AE CRF02_AG CRF25 Unknown G CRF02_AG 
CM-05 G G CRF02_AG G G CRF02_AG 
CM-08 G CRF02_AG G Unknown G CRF02_AG 
CM-09 F2 F2 F2 Unknown F2 F 





Sample jPHMM COMET SCUEAL REGA RIP Stanford 
CM-014 C C C C C C 
CM-016 G G CRF02_AG Unknown G CRF02_AG 
CM-16 G CRF02_AG G Unknown G G 
CM-017 G G CRF02_AG Unknown G CRF02_AG 
CM-17 CRF01_AE CRF02_AG CRF01_AE Unknown G CRF02_AG 
CM-019 C CRF45-CPX G / K Unknown CPX K 
CM-19 C C C C C C 
CM-021 G G G G G G 
CM-21 A1 A1 CRF22 A (A1) A1 CRF01_AE 
CM-24 G G CRF02_AG Unknown G CRF02_AG 
CM-29 A1 / G CRF02_AG A1 / G. Unknown G CRF02_AG 
CM-30 A1 A1 CRF22 A (A1) A1 CRF01_AE 
CM-31 G G CRF02_AG Unknown G CRF02_AG 
CM-32 A1 A1 CRF22 A(A1) A1 CRF01_AE 
CM-33 G G CRF02_AG G G CRF02_AG 
CM-39 A1 A1 CRF22 A (A1) A1 CRF01_AE 
CM-44 G CRF02_AG A4 / G. Unknown G CRF02_AG 
CM-47 G G G G G G 
CM-57 A1 A1 CRF01_AE A (A1) A1 CRF01_AE 
CM-177 F2 F2 F2 Unknown F2 F 
CM-510 G CRF02_AG CRF02_AG Unknown G CRF02_AG 









Table 3.5 Summary of HIV-1 subtype analyses based on pol (IN) fragment using five 
different online programmes.  
Sample HIV subtype analyses 
 jPHMM COMET SCUEAL REGA Stanford 
CM-02 G G G G CRF02_AG 
CM-03 G G G G G 
CM-05 G G CRF36 G CRF02_AG 
CM-09 F2 F2 F1 Unknown F2 
CM-013 A1 A1 CRF19 A1 D 
CM-016 G G CRF36 G CRF02_AG 
CM-017 G G G G CRF02_AG 
CM-17 G G CRF02 Unknown CRF02_AG 
CM-19 C C C C C 
CM-020 B B B B B 
CM-20 G G CRF02 Unknown CRF02_AG 
CM-021 G G G G CRF02_AG 
CM-24 A1 A1 AE Unknown CRF06_cpx 
CM-28 G G G G G 
CM-29 G G G G CRF02_AG 
CM-30 C C CRF22 Unknown CRF06_cpx 
CM-31 G G G G CRF02_AG 
CM-32 A1 A1 CRF22 Unknown CRF06_cpx 
CM-33 G G G G CRF02_AG 
CM-39 A1 A1 CRF22 Unknown A 
CM-43 G G Unknown G CRF02_AG 
CM-44 G G G G CRF02_AG 





Sample jPHMM COMET SCUEAL REGA Stanford 
CM-47 G G G G CRF02_AG 
CM-48 G G G G CRF02_AG 
CM-57 A1 A1 CRF22 Unknown A 
CM-177 F1 F1 F2 Unknown F2 
CM-220 A1 A1 CRF22 Unknown CRF11_cpx 
CM-SubO Unknown O O O O 
*CM-013 subtyped as A1 by jPHMM, COMET and REGA programs while SCUEAL and 
Stanford subtyped as CRF19 and D respectively. 
*CM-SubO was the only sequence subtyped as HIV-1 group O based on the IN 
fragment. 
 Group O sample 
One sample from the 28 analyzed IN fragments was identified as HIV-1 group O, as 
indicated by REGA and RIP subtyping tools (Figure 3.9 and Figure 3.10). Other 
subtyping programs that could identify this subtype include COMET, SCUEAL, REGA 
and Stanford (CM-SubO in Table 3.5). The other 2 subtyping programs (jpHMM and 
RIP) would not assign the sequence to any HIV-1 subtype as the nucleotide 
sequence was not long enough. 






Figure 3.9 A sample sequence (Sample_SubO) assigned based on 312bp with a 
bootstrap of less than 70.0%. The sample sequence clustered to HIV-1 group O in the 
pol (IN) fragment (light blue in color) using REGA subtyping program.  
 
Figure 3.10 HIV-1 group O screened using RIP subtyping program. The background 
contains consensus and subtype reference sequences of HIV-1 subtypes. 
 





 Phylogenetic analyses  
A phylogenetic evaluation for all 23 pol RT samples using neighbor-joining tree was 
reconstructed using MEGA version 5 with 1000 bootstrap replications (Figure 3.11). 
The majority of the sample sequences clustered with HIV-1 subtype G which 
accounted for 56.2% (n = 18), Subtype A 19.0% (n = 6), Subtype C and F2, 9.4% 
each (n = 3) and 2 subtype D (6.0%). The four subtypes observed are well illustrated 
in specific subtrees as indicated in Figure 3.12, 3.13, 3.14 and 3.15. Four of the 
sequenced samples could not be assigned to any subtype with confidence.  






Figure 3.11 Phylogenetic relationship of the pol (RT) gene fragment of 450 bp in 23 
samples (in bolder circles), clustered with HXB2 reference strains from los alamos 
database. The tree was drawn with Mega v 5 using Kimura 2 parameter and bootstrap 
performed in 1000 replicates. The tree was rooted to an outlier (group O). Four 
confirmed HIV-1 group M subtypes were characterized and include; G/CRF02_AG at 
62.5% (n = 15), A (20.8%; n = 5), C (8.3%; n = 2) and F2 (8.3%; n = 2). 






Figure 3.12 A phylogenetic subtree indicating HIV-1 group M subtype G samples 
(02,03,08,013,016,17,017,021,24,29,31,33,47 and 510) clustered with HXB2 
references in pol (RT fragment). 






Figure 3.13 A phylogenetic subtree indicating HIV-1 group M subtype F1 samples (09, 
019 and 177) clustered with HXB2 references in pol (RT fragment). 






Figure 3.14 A phylogenetic subtree indicating HIV-1 group M subtype C samples (014 
and 19) clustered with HXB2 references in pol (RT fragment). 
 
Figure 3.15 A phylogenetic subtree indicating HIV-1 group M subtype A1 samples (21, 
30, 39 and 57) clustered with HXB2 references in pol (RT fragment). 





 HIV-1 drug resistance associated mutations in the pol (PR, RT and IN) 
genome 
The 3 fragments of the pol gene (PR, RT and IN) were genotypically analysed for 
presence of various RAMs. The pol genome is a conserved region that is found with 
mutations that act against the commonly used cART (PIs, RTIs – NRTIs/NNRTIs and 
INIs). In the overall, 29, 27 and 28 sample sequences were screened for RAMs in the 
PR, RT and IN fragments respectively based on HIV Stanford Drug resistance data 
base (Table 3.6 and 3.7).  
3.9.1 Protease RAMs 
There was no major RAM observed in all 29 PR sequences analyzed while a total of 
33 minor PIs RAMs were identified in 25 out of 29 (86.0%). These minor PIs were 
grouped into 8 types according to the Stanford HIV DR Database and they include; 
L10I, K20I, L10V, K20M, V11I, V11IV, G48GR and K20IK (Table 3.6). The L10I RAM 
is a polymorphic accessory mutation that increases the replication of viruses while 
K20I is a PI-selected accessory mutation that reduces NFV susceptibility. The V11I is 
a non-polymorphic PI-selected mutation associated with reduced DRV and FPV 
susceptibility when it occurs in combination with other PI-resistance mutations. The 
role of other minor PI mutations - L10V, K20M, V11IV, K201K and G48GR in drug 
resistance is under investigation. A summary of number of PR RAMs and their 
equivalent percentages is indicated in Figure 3.16.  
 
 





Table 3.6 Minor PI RAMs as observed in the PR region of the HIV-1 genome using 
Stanford HIV Drug Resistance database 
Sample ID DRMs 
 
Major resistance Minor resistance 
CM-02 NONE L10I,K20I 
CM-03 NONE K20I 
CM-05 NONE K20I 
CM-08 NONE K20I 
CM-09 NONE L10V 
CM-011 NONE K20M 
CM-013 NONE V11I,K20I 
CM-014 NONE NONE 
CM-016 NONE K20I 
CM-16 NONE K20I 
CM-017 NONE V11IV,K20I 
CM-17 NONE K20I 
CM-19 NONE K20I 
CM-20 NONE K20I 
CM-21 NONE NONE 
CM-24 NONE K20I 
CM-29 NONE L10I,K20I 
CM-30 NONE NONE 
CM-31 NONE K20I 
CM-32 NONE L10I 
CM-33 NONE L10V,V11I,K20I 
CM-39 NONE L10I 





Sample ID Major resistance Minor resistance 
CM-44 NONE K20I 
CM-45 NONE NONE 
CM-47 NONE K20I 
CM-48 NONE K20I 
CM-52 NONE K20I, G48GR 
CM-57 NONE K201K 
CM-177 NONE V11I,K20I 




Figure 3.16 Summary of the percentages of minor PI RAMs observed in 25 out of 29 
sequences analysed. Some samples had more than one RAM as observed in sample 
CM-02, CM-013 and CM-017 in Table 3.6 above.  





3.9.2 NRTIs and NNRTIs RAMs 
Both NRTI and NNRTI RAMS were observed in this study cohort with 27 RT 
sequences analyzed (Table 3.7). The NRTI mutations (only observed in one patient) 
included K65R, T215I and K219E; while the NNRTI resistance associated mutations 
were observed in 11 out of the 27 sequences (40.7%). The NNRTI mutations noticed 
were; V106M, Y181C and Y188H with each observed at 6.7% in the study population 
(Figure 3.17). The other NNRTI RAMs included the V90I at 20.0% and V179E at 
13.3%. A number of other polymorphisms that were not necessarily associated to any 
drug resistance were also observed, and they include; E138A (13.3%), V179D 
(6.7%), V108I (6.7%), V106I (6.7%) L100IL (6.7%) and V90IV (6.7%) (Figure 3.17). A 
summary of drug resistance to both PIs, and NRTI/NNRTI RAMs in this study cohort 
is below (Figure 3.18). 
Table 3.7 Resistance Associated Mutations against RT genomic region using 
Stanford HIV Drug Resistance database 
Sample Major DRMs 
 
NRTI NNRTI 
CM-02 NONE V179D 
CM-03 NONE NONE 
CM-05 NONE V90I,V179E 
CM-08 NONE NONE 
CM-09 NONE NONE 












CM-016 NONE V90I,V179E 
CM-16 NONE NONE 
CM-017 NONE V90I 
CM-17 NONE NONE 
CM-019 NONE NONE 
CM-19 NONE V108I 
CM-021 NONE V106I 
CM-21 NONE E138A 
CM-24 NONE NONE 
CM-29 NONE NONE 
CM-30 NONE NONE 
CM-31 NONE NONE 
CM-32 NONE NONE 
CM-33 NONE L100IL 
CM-39 NONE NONE 
CM-44 NONE V90IV 
CM-47 NONE NONE 
CM-57 NONE NONE 
CM-177 NONE E138A 
CM-510 NONE NONE 
*CM-014 is the only patient with multiple drug resistance mutations against nearly all 
NRTIs and NNRTIs available approved by FDA. 
 






Figure 3.17 Summary of the percentages of NNRTI observed in 11 out of 27 RT 
sequences with E138A and V179E mutations with high frequency of occurrence. 
The V179E is a non-polymorphic mutation that is occasionally selected by NVP 















        Infant/Children: Level of drug resistance against NRTIs/NNRTIs 
 
Figure 3.18 Observed drug resistance against RTIs (NRTI and NNRTIs). 
Majority of study participants (over 95.0%) were susceptible to all NRTIs while 
3.7% had low level resistance to 3TC and intermediate to high level resistance 
to ABC, FTC and TDF. Approximately 55.0% were susceptible to NNRTIs while 
40.7% of study participants had low level to potential low level resistance to 
EFV, ETR, NVP and RPV. Less than 3% had intermediate to high level 
resistance in RPV and NVP respectively. 
3.9.3 Integrase RAMS 
One sample (CM-020) was observed with a major resistance mutation E92EG which 
indicates intermediate resistance to Elvitegravir (EVG), low-level resistance to 





Raltegravir (RAL) and susceptible to Dolutegravir (DTG). The other sample CM-33 
showed accessory resistance mutation E157Q which is a polymorphic mutation with 
potential low-level resistance to Elvitegravir (EVG) but susceptible to Dolutegravir 
(DTG).   
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 Overview of the study 
This study focused on characterizing HIV diversity and drug resistance patterns from 
a cohort of therapy naïve infected infants from Yaoundé, Cameroon. The majority of 
infants (74.0%) were from the rural areas, while 26.0% were from the urban area. 
The urban areas (in this case - are patients from referral hospitals within Yaoundé 
city that include the mother and child center of the Chantal Biya Foundation (FCB) 
and the CSCCD research institute - both associated with Yaoundé 1 University 
Teaching Hospital. These two health institutions receive a high number of HIV 
positive patients due to better infrastructure and easy accessibility, especially - FCB 
of Cameroon -which receives support from the First lady, Mrs. Chantal Biya. Patients 
from rural areas visits district hospitals serving within those regions and include 
l'Hospital de district de la Cité Verte, l'Hospital de district d'Efoulan and l'Hospital de 
district de Biyemi-Assi. For the purpose of this study, the HIV-1 pol PR, RT and IN 
were examined to determine HIV diversity and drug RAMs that are currently 
circulating within this study cohort. The pol PR, RT and IN genome is a conserved 
region good for diversity studies and is also characterized with a variety of RAMs that 
inhibit the effectiveness of the commonly used cART regimens. Given that there are 
new HIV infections reported in this region, continuous HIV characterization and drug 









 HIV diversity   
In this study cohort, the partial pol genomic regions (PR, RT and IN) were analysed 
for HIV-1 subtype inference. Majority (25/32, 75.7%) of sequenced samples were 
characterized by most of the online programs with concurring subtypes. Some of the 
sequences analysed were classified into the following subtypes and CRFs; 
CR02_AG, G, A, C, G, F1/F2 and CR02_AG. The major difference was observed in 
sample CM-013 that showed multiple subtypes in all the three fragments by each 
subtyping program.  
 Observed HIV subtypes using various online subtyping programs 
The online subtyping programs – jpHMM (https://comet.lih.lu/), REGA 
(http://dbpartners.stanford.edu:8080/RegaSubtyping/stanford-hiv/typingtool/) 
SCUEAL (http://www.datamonkey.org/dataupload_scueal.php), RIP 
(http://www.hiv.lanl.gov/content/sequence/RIP/RIP.html). COMET 
(https://comet.lih.lu/)) and Stanford (https://hivdb.stanford.edu/hivdb/by-mutations/)-, 
were able to infer various subtypes in the majority of patient samples. In jpHMM, 
SCUEAL, COMET and Stanford subtyping programs all sequenced samples from the 
three pol (PR, RT and IN) fragments were inferred with a subtype. In RIP subtyping 
program, 69.0% and 96.5% of sequenced samples for PR and RT, respectively were 
inferred with a subtype, but in the pol (IN) fragment, none of all the sequenced 
samples were characterized. This was attributed to the short sequences (less than 
300bp) obtained in the amplification of the IN fragment across all sample cohort. The 
REGA subtyping program was successful in 27.6%, 48.0% and 71% for PR, RT and 





IN fragments, respectively, while SCUEAL was successful in all RT and IN fragments 
and 89.7% for PR fragment across all amplified and sequenced samples. There was 
uniformity in the majority of subtype inference, for example - all subtyping programs 
inferred patient CM-014 as subtype C. In a study done from Portuguese HIV Drug 
Resistance Database in comparing various online subtyping programs, pure subtype 
B and C had more than 95% sensitivity and specificity than other subtypes (Pineda-
Pena AC.et al., 2013). The major discrepancy in subtype inference for all subtyping 
programs used for this study was observed in sample sequence CM-013, where the 
jpHMM subtyping tool inferred the PR and IN fragments as subtype A1, while the RT 
fragment was clustered as B/G. The RIP subtyping tool inferred similar sample 
sequence (CM-013) as subtype G and D for RT and IN, respectively while on the PR 
fragment it was unknown. The REGA subtyping tool clustered the sample sequence 
as subtype A1 based on the IN fragment while the PR and RT were unknown. The 
SCUEAL inferred the same sample sequence as subtype CRF37, G and CRF19 for 
PR, RT and IN respectively while COMET inferred it as FI, D and A1 for PR, RT and 
IN respectively. Finally, the Stanford subtyping tool inferred the same sample 
sequence as CRF02_AG, G and D for PR, RT and IN respectively. Cases like this of 
sample sequence CM-013 makes it difficult to completely rely on the subtyping 
programs because of instances of inability to infer specific subtype to a particular 
sample sequence or ambiguity in subtype inference for the same sample sequence. 
Online subtyping programs fail to infer subtype either because the sample sequence 
is a recombinant and cannot be assigned to any specific subtype or the length of the 
sample size is small for the algorithm to cluster it. To solve this problem, the use of 
phylogenetic trees to confirm the subtype is very crucial and this can be done either 





through distance based analysis like for example use of  NJ phylogenetic tree or by 
character based analysis like for example the Maximum likelihood (ML)  phylogenetic 
tree. In patient CM-013 described above, the NJ phylogenetic tree was used and it 
was confirmed to be subtype A. 
 Neighbor – Joining phylogenetic inference 
A NJ phylogenetic tree confirms subtypes observed using online programs. It gives 
information on similarities and differences of nucleotide sequences from their original 
ancestor, which are displayed in a phylogenetic tree. The confidence of the topology 
is based on the bootstrap value, which should be over 75.0% in sequences of the 
same clade. In this cohort, two HIV-1 groups were observed - group M and group O. 
In group M, four distinct subtypes were detected and they included; G/CRF02_AG, A, 
C and F2. The observed mosaic of HIV-1 subtypes in this study cohort, corroborates 
with other previous findings confirming the wide presence of HIV diversity in this 
region (Ndembi et al., 2008; Vallari et al., 2011; Hemelaar et al., 2011). The most 
predominant strain was G/CRF02_AG (n = 15; 62.5%), remaining the most 
circulating recombinant form in this study cohort. This high prevalence of 
G/CRF02_AG corresponds with other studies in Cameroon (Ndembi et al., 2008; 
Carr et al., 2010; Fokam et al., 2011; Ragupathy et al., 2011; Vallari et al., 2011). The 
CRF02_AG is a complex mosaic of HIV with alternating subtype A and G sequences 
(Agyingi et al., 2014). Other subtypes were less predominant, with A (n = 5, 20.8%), 
C (n = 2, 8.3%), and F2 (n = 2, 8.3%). Of interest was the presence of HIV-1 group O 
and HIV-1 group M subtype C. Group O in patient SubO was characterized based on 
an IN sequence, while subtype C in patient CM-014 was observed in all pol (PR, RT 





and IN) fragments. HIV-1 group M subtype C is uncommon in this region and 
comparing the small sample size that was available for this study and the partial 
amplification of the pol fragment, it could be high. This raises concern over other 
transmissions and the geographical distribution of HIV, which could be due to the 
cosmopolitan nature of the city of Yaoundé and the large number of migrants from 
neighboring cities within Central Africa. 
4.4.1 Group O sequence 
HIV-1 group O represents 1.0% of all global infections (Vessiere et al., 2010; 
Yamaguchi et al., 2004). It is commonly confined to west and central Africa and more 
common in Cameroon (Leoz et al., 2015). It could be possible that the presence of 
group O is underestimated due to inadequate screening procedures. In molecular 
characterization, HIV group O can easily remain undetected due to the complexity of 
designing the right molecular assays and primers for RNA amplification and 
sequencing. In the single case that was identified as group O in this study, it was 
clustered using only two subtyping program tools - REGA and RIP based on the pol 
(IN) fragment. Other subtyping tools like COMET, SCUEAL, REGA, jpHMM, RIP and 
Stanford would not cluster the sequence to any HIV subtype possibly because the 
nucleotide sequence was not long enough (only 300bp was available). HIV near full-
length genome (NFL) analysis is necessary to confirm whether it is a pure HIV-1 
group O. The other pol fragments (PR and RT) of the same sample were also 
unsuccessfully amplified due to primer failure and therefore missing more information 
on sample sequence characterization. There were challenges with PCR amplification 
of the same sample due to lack of appropriate primers or even designing them. The 





small amount of sample was a huge limitation in performing further molecular 
analysis – like checking whether it is a recombinant. Group O is the most diverse of 
HIV-1 subtypes after group M. The routine serological methods for testing group O 
subtype are not effective as majority indicate negative results. Molecular 
characterization is more reliable in diagnosing this subtype and this is important in 
controlling the spread of this subtype which recent studies show that it is becoming a 
major concern in HIV control (Villabona-Arenas et al., 2015). 
 HIV-1 immunologic and virological markers 
Most resource-limited countries, such as Cameroon, rely on WHO guidelines of 
clinical symptoms and viral load to monitor patients failing first or second-line cART. 
This is exactly the opposite in developed countries that have adopted routine viral 
load screening as a gold standard in diagnosing immunologic of virologic failure. 
According to the 2013 WHO guidelines that have been adopted by Cameroon, it 
regards immunologic failure in children perfectly adhering to treatment as those with 
CD4 count less than 200 cells/mm3 or CD4 percentage of less than 10.0% in children 
less than 5 years. In children more than 5 years, CD4 count less than 100 cells/mm3 
is regarded as immunological failure. In virological failure under the same 2013 
guidelines, it refers to those children following adequate treatment but with viral loads 
above 1000 RNA copies/ml after at least 24 weeks under cART. In this study Cohort, 
most of the children had CD4 percentage and absolute values within the therapeutic 
normal range (> 30.0% and >500 copies/ml). The value confers their immune-
competent status as outlined in the WHO and CDC treatment guide for HIV 
immunological staging [(WHO, 2015: Country report:  





(http://www.who.int/countries/cmr/en/)]. On the other hand, the majority had high viral 
load approaching 1000 RNA copies/ml mark but cannot be termed as virological 
failure, since they are not on treatment according to the 2013 WHO guidelines. The 
risk of such high viral load may not be well understood, especially when they start 
treatment. The CD4 values and as also indicated in other studies, suggests that the 
use of CD4 percentage and / or absolute values should be re-evaluated when 
decisions are made to start cART in limited resource settings (Takow et al., 2013). 
There was no correlation between CD4 cell percentage counts and viral-loads in this 
study. 
 cART for infants/children in Cameroon  
First line treatment for infants under 3 years in Cameroon includes two NRTIs: ABC 
or AZT plus 3TC with LPV/r as a PI which are combined in the first-line cART 
regimen with a NNRTI: EFV or NVP. The PI include LPV/r. In the alternative first-line 
therapy, only EFV is replaced with NVP. In the second-line therapy, treatment is 
based on NNRTI used in first-line therapy and the preferred regimen is ABC or TDF 
plus 3TC plus LPV/r. In children over 3 years to 10 years, the first line therapy 
includes ABC plus 3TC plus EFV and alternative being AZT or TDF plus 3TC or FTC 
plus EFV or NVP. In the second line of treatment, AZT or ABC plus 3TC plus LPV/r 
with a replacement of TDF plus 3TC plus LPV/r has been adopted. Drug resistance 
on the above currently used class of drugs in this study cohort from Cameroon is 
described in the section 4.5 below in relation to corresponding observed resistance 
associated mutations. 





 Resistance associated mutations and polymorphisms in Cameroon  
RAMs observed in this study cohort include 25/29 (86.0%) patients for minor PIs, one 
patient (1/27, 3.7%) for NRTIs and 11/27 (40.7%) patients for NNRTIs while 2/28 
(7.1%) patients had RAMs against INIs. Some of NRTI RAMs observed in this study 
cohort like K65R, T215I and K219E (which is an accessory Thymidine analogue 
mutation) and NNRTI RAMs like V179D, V106M and Y181C have also been 
observed in other studies done in Cameroon (Laurent et al., 2006; Fokam et al., 
2013). A Single NRTI mutation like K65R is responsible for high-level resistance to 
majority of drugs like TDF, ddI and ABC while K219E mutation is associated with 
reduced susceptibility to drugs like AZT and possibly d4T (Larder & Kemp, 1989; 
Kuritzkes et al., 2000). Due to high diversity as observed in this study, it may difficult 
to identify all mutations that are relevant as described in subsequent sub-sections 
below.  
4.7.1 Protease mutations 
There were no major RAMs observed in all 29 PR sequences analyzed, while a total 
of 33 RAMs against minor PIs were identified in 25 out of 29 (86.0%) analysed 
samples. These minor PIs were grouped into 8 types and they include; L10I, K20I, 
L10V, K20M, V11I, V11IV, G48GR and K20IK. The L10I RAM was observed in 4 / 33 
PIs RAMs (12.2%), and is a polymorphic accessory mutation that increase the 
replication of viruses with other PI- RAMs, while K20I was observed in 20/33 PI 
RAMs (60.6%) and is a consensus amino acid in subtype G and CRF02_AG.  In 
subtype C, the K20I is a PI-selected accessory mutation that reduces NFV 





susceptibility. The V11I (n = 3; 9.1%) is a non-polymorphic PI-selected mutation 
associated with reduced DRV and FPV susceptibility when it occurs in combination 
with other PI-resistance mutations. Other minor mutations observed in the PR 
fragment included; L10V (n = 2; 6.1%), K20M (n = 1; 3.0%); V11IV (n = 1; 3.0%) 
G48R (n = 1; 3.5%) and K201K (n = 1; 3.0%) - and their role in drug resistance has 
not yet been fully studied. 
4.7.2 Reverse transcriptase mutations 
The Reverse transcriptase mutations are grouped into two - NRTI or NNRTI RAMs 
and both cause drug resistance. The NNRTI cause resistance to ABC, AZT, FTC, 
3TC and TDF while NNRTI RAMs can cause resistance to EFV, ETR, NVP and RPV 
In the 27 RT sequences analyzed, one patient (CM-014) had multiple major NRT and 
NNRTI resistance associated mutations. The NRTI mutations observed for this 
patient were K65R, T215I and K219E. The K65R mutation indicates high-level 
resistance to TDF, DDI and D4T, but low to intermediate-level resistance to 3TC and 
FTC. The T215I mutation indicates intermediated to high-level resistance to AZT and 
D4T, with low-level resistance to ABC, DDI and TDF. The K219E mutation, with 
accessory TAMs, is associated with reduced susceptibility to AZT and possibly to 
D4T. These mutations indicate that this patient is highly resistant to all current 
classes of NRTI and NNRTI drugs. The NNRTI resistance associated mutations were 
observed in 11 out of the 27 sequences (40.7%). These included the mutations 
V106M, Y181C and Y188H with each observed at 6.7% in the study population. The 
V106M mutation indicates high-level resistance to NVP and EFV, Y181C indicates 
reduced susceptibility to NVP, ETR, RPV and EFV, while Y188H indicates reduced 





susceptibility to NVP and EFV. The other NNRTI RAMs included the V90I at 20% and 
is a polymorphic accessory mutation with minimal detectable reduction in NNRTI 
susceptibility. The V179E was at 13.3% and is a non-polymorphic mutation that is 
occasionally selected by NVP and EFV inhibitors. Some of these mutations like 
Y188H and Y181C have previously described in other studies conducted in 
Cameroon (Laurent et al., 2006; Aghoken et al., 2013). A number of other 
polymorphisms that were not necessarily associated to any drug resistance were also 
observed, and they include; E138A (13.3%), V179D (6.7%), V108I (6.7%), V106I 
(6.7%) L100IL (6.7%) and V90IV (6.7%).  
4.7.3 Integrase mutations 
There was one major resistance associated mutations (E92EG) observed in patient 
CM-020. This mutation showed intermediate resistance to Elvitegravir (EVG) and 
low-level resistance to raltegravir (RAL), but was susceptible to Dolutegravir (DTG). 
Another patient CM-33 had the E157Q mutation, which is a polymorphic mutation 
with potential low-level resistance to Elvitegravir (EVG), but susceptible to 
Dolutegravir (DTG). This patient had NNRTI mutation – L100IL and PI mutations – 
L10V, V11I and K20I. The E157Q mutation has been observed in CRF01_AE 
subtypes, which are common in West Africa region and in a study done in Cambodia 
showing resistance to RAL and EVG drugs (Maiga et al., 2009; Nouhin et al., 2011). 
Since there are no INIs currently prescribed in Cameroon and many other resource-
limited settings as per the 2013 WHO guidelines, it is likely that these mutations may 
have a negative impact in future if the same drugs are used in managing these 





patients. The INIs have shown to be useful for salvage therapy and apparently less 
prone to resistance (Geretti et al., 2012; Dow & Bartlett, 2014). 
 Impact of this study cohort in HIV management 
Despite concerted efforts by the Cameroon government and other international 
agencies, such as UNAIDS, in stopping HIV transmissions from mother-to-child, a 
significant number of children are still born with HIV, as observed in this study. 
Furthermore, one child had high level of drug resistance to almost all classes of 
cART. This is a big challenge especially in resource-limited countries like Cameroon, 
where few alternative cART regimens are available. This data can therefore be used 
in strengthening HIV prevention programs, like PMTCT, especially in the rural areas 
where few facilities are available. High prevalence of HIV diversity in Cameroon as 
observed in this study and other previous studies is a challenge in providing standard 
laboratory operating procedures as most assays are based on subtype B. The 
continuous presence of these diverse subtypes is a call to policy makers and 
international community to channel more resources in research on subtype 
association with new HIV infections being reported in Cameroon and elsewhere. 
Drug resistance in Cameroon is associated with non-adherence to cART or due to 
transmitted drug resistance associations. HIV resistance is also directly related to the 
rapid scale up of cART (Chaix et al., 2007; Fokam et al., 2011; Kityo et al., 2016). 
Access to genotyping and resistance assays can help manage HIV patients failing 
cART by providing baseline knowledge on the RAMS detected in the patient.  
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Study participants in this cohort were therapy naïve adult males and females of ages 
between 15 to 50 years old from Cameroon. The settings were the same as for those 
in cohort I as briefly described below. The CD4 count and viral load estimation was 
not performed due to lack of sufficient assays to carry out the respective laboratory 
procedures. Furthermore, only PR and RT were amplified and sequenced. The IN 
which was part of the pol fragment for analysis, was not done due to time constraints 
and funding for the project. 
 Ethical statement 
There was one Ethical clearance covering letter for both cohorts as indicated in 
section 2.2.  
 Study design 
This was also a cross-sectional study in the same period and settings as Cohort I in 
section 2.3.  
 Study participants 
These were 125 therapy naïve adult - 43 Males and 83 Females totaling to 125 study 
participants (n = 125), with their ages ranging between 15 to 50 years old.  
 Equipment, chemicals, reagents, commercial assays and enzymes 
The list was the same as in Cohort I in section 2.5; Table 2.1, Table 2.2, Table 2.3, 
Table 2.4, Table 2.5 and Table 2.6. 





 Sample collection, preparation and storage 
Ten ml of whole blood from all 125 participants was drawn, stored and shipped to the 
Division of Medical Virology at University of Stellenbosch for further analysis as in 
cohort I in section 2.6. Due to inadequate laboratory assay kits for CD4 and viral load 
assays, CD4 and viral loads were not done. 
 Viral RNA extraction  
Viral RNA was extracted from 125 plasma samples using the same standard 
operating procedures as in Cohort I section 2.6.3. 
 Viral RNA concentration and estimation 
Viral RNA concentration and estimation was done so as to obtain a high yield of pure 
RNA and to remove other protein impurities or contaminants that would affect 
downstream procedures. Viral estimation was performed as described in Cohort I 
section 2.6.5. 
 Location of genome of interest (pol genome) 
To characterize the HIV subtypes and drug resistance testing for this study Cohort, 
the pol genome (PR and RT) fragments was the focus as indicated on the HXB2 
gene map location in Cohort I section 2.7, Figure 2.4.  
 PCR amplification 
Both PCR reactions for RNA amplification (Pre-nested and Nested PCR) were run as 
indicated in Cohort I section 2.8 - the master mix preparation and cycling conditions 





were as Table 2.9 and Table 2.10 for pre-nested PCR, while Table 2.11 and Table 
2.12 were for nested PCR. The specific primers used for both runs are indicated in 
Table 2.5 and Table 2.6 for PR and RT, respectively as in Cohort I.  
 Detection and purification of PCR amplicons (PR and RT)  
PCR amplifications were performed in 2 pol gene (PR and RT) fragments and 
positive bands visualized as in Cohort I section 2.8.3. Purification of PR and RT 
amplicons from excess primers, enzymes, nucleotides, polymerases and salts were 
performed as in Cohort I section 3.1.11. The eluted purified DNA for all the two 
fragments pol (PR and RT) were kept at -20oC for subsequent downstream 
procedures.  
 Sequencing  
All amplified adult samples obtained from the pol gene (PR and RT) were subjected 
to DNA sequencing which is based on the selective chain-determination of Sangers 
sequencing as performed in Cohort I section 2.9.  The sequencing primers and PCR 
cycling parameters used were as indicated in Cohort I Table 2.12 and Table 2.13, 
respectively.  
 Quality control  
To exclude contamination of sample DNA sequences obtained for this cohort study, 
all DNA sequences were subjected for quality check using los alamos laboratory data 
base (http://www.hiv.lanl.gov) as described in Cohort I Section 2.10.  
 






Overlapping DNA fragments were assembled after manual bio-editing using 
Sequencer version 5.0 with default parameter settings of sequence quality above 
75.0% as in Cohort I section 2.10. Multiple alignments were created using MAFFT 
version 7 (http://mafft.cbrc.jp/alignment/server/) with HXB2 sequences used as 
reference. 
 Preliminary HIV-1 subtyping using online programs 
Six online subtyping tools for HIV, which included COMET, jpHMM, SCUEAL, RIP, 
REGA and Stanford were used for preliminary HIV-1 subtypes as performed in 
Cohort I section 2.11. 
 Phylogenetic inference 
To evaluate the relationship between the study cohort sequences and the currently 
available reference sequences, a Neighbor-Joining (NJ) phylogenetic tree was drawn 
using MEGA v.5 as described in cohort I section 2.13.  
 Drug resistance analyses 
DNA sequences from the partial pol gene (PR and RT) fragments from positively 
amplified patient samples were subjected to the Stanford HIV drug resistance online 
programs as described in Cohort I section 2.12.  The PI, NRTI and NNRTI RAMs 
were analysed and the data tabulated as indicated in Chapter 6, section 6.5 below.  
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 Positively amplified pol gene (PR and RT) fragments 
Of the 125 samples collected for this study cohort, there were 73/125 (58.4%) 
amplified amplicons for at least one of the two pol gene fragments. Specifically, 
59/125 (47.2%) were positively amplified for PR, while 55 (44.0%) were amplified for 
the RT fragment. A summary of amplified amplicons for each of the two pol genes 
(PR and RT) fragments for this cohort is shown in Table 6.1. Examples of positive 
amplicons on the gel photo are shown in Figure 6.1 and 6.2. 
Table 6.1 Summary of positively amplified pol gene fragments (n = 125) 
Fragment Number of samples out of 125 %age 
Atleast 1 fragment amplified 73 58.4% 
PR 59 47.2% 
RT 55 44.0% 










Figure 6.1 Partial pol (PR) fragment of 514 bp length in 1.0 % TAE agarose gel 
picture. An example of positively amplified samples that include numbers; 47, 49, 
50,51,52,53,54,55,56 and 59 while samples number 48, 57 and 58 are examples that 
could not be amplified with available PR primers. One kilo-base (1kb) DNA ladder 
indicated as M showing different bands of corresponding DNA concentration in 
nanograms (ng), was used as DNA marker (DM). MJ4 plasmid positive control (PC) 
and Non-template control (NTC) were included as controls. The gel was stained with 
GRGreen Nucleic Acid Gel Stain. 
 
Figure 6.2 Partial pol (RT) fragment of 804 bp length in 1.0 % TAE agarose gel 
picture. An example of positively amplified samples that include numbers; 41-43, 
46,53,56,57 and 59 while an example of sample 58 would not be amplified with 
available RT primers. One kilo-base (1kb) DNA ladder showing different bands of 
corresponding DNA concentration in nanograms (ng) was used as DNA marker (M). 
MJ4 plasmid positive control (PC) and Non-template control (NTC) were included as 
controls. The gel was stained with GRGreen Nucleic Acid Gel Stain. 





 Sequencing and alignment 
After DNA sequencing of cohort II sample sequences, multiple alignment was done 
using MAFFT version 7 and an example of aligned sequences with HXB2 references 
from los alamos data base sequences is given below in Figure 6.3 
 
Figure 6.3 An example of Nucleotide sequences of PR fragment from 18 adult 
patients (PR SN51, SN52, SN53, SN54, SN55, SN59, SN61, SN62, SN63, SN64, 
SN66, SN67,SN68, SN70,SN71,SN81 and SN91). The sequences are aligned with 
HXB2 reference sequences using MAFT V7.0 online program.  
 





 Preliminary HIV-1 subtyping using various online programs 
As indicated in the methods in section 5.13, the HIV-1 subtyping analysis was run 
using COMET (https://comet.lih.lu/), jpHMM (http://jphmm.gobics.de), SQUEAL 
(http://www.datamonkey.org/dataupload_scueal.php), REGA 
(http://dbpartners.stanford.edu:8080/RegaSubtyping/stanford-hiv/typingtool/-), RIP - 
(http://www.hiv.lanl.gov/content/sequence/RIP/RIP.html) and Stanford 
(https://hivdb.stanford.edu/hivdb/by-mutations/) online subtyping programs. An 
example of a preliminary HIV subtyping using REGA, jpHMM and RIP online 
subtyping tools is shown below in Figure 6.4, 6.5 and 6.6 respectively. The sample 
sequence is of the Pol (PR) fragment from patient SN52. Other online programs as 
indicated in cohort I section 3.17 do only show HIV subtype without HXB2 gene map 
location. A summary of HIV subtypes based on the six online tools for PR and RT 
fragments is tabulated in Table 6.2 and 6.3 respectively. Highlighted on Table 6.2 are 
PR sample sequences that include SN17, SN18, SN21, SN24, SN26, SN39 SN54, 
SN55, SN132 and SN148 with different subtypes as assigned by each subtyping 
program. Sample sequences for SN03, SN63 and SN224 on Table 6.3 are based on 
RT fragment and were assigned different subtypes using the online subtyping 









Table 6.2 PR Fragment for Cohort II 
 HIV Subtypes Using six Online Subtyping Programs 
No. Sample 
ID 
jPHMM COMET SCUEAL REGA RIP Stanford 
1. SN03 F2 F2 F2 Unknown Unknown F2 
2. SN16 G CRF02_AG G Unknown G CRF02_AG 
3. SN9 G G CRF13 Unknown G CRF13_CP
X 
4. SN10 A1 CRF02_AG CRF09 Unknown Unknown A 
5. SN17 A1F1 C CRF37 Unknown G G 
6. SN18 A1 F1 G Unknown Unknown CRF02_AG 
7. SN21 01_AEA
1G 
F1 G Unknown Unknown CRF02_AG 
8. SN24 G B Complex Unknown G CRF02_AG 
9. SN26 CF1 A1 CRF02 Unknown Unknown CRF02_AG 
10. SN32 01_AEG CRF02_AG AE, G 
reco 
Unknown G CRF02_AG 
11. SN34 G A1 G Unknown Unkown CRF02_AG 
12. SN35 AIG A1 Complex  Unknown G CRF02_AG 
13. SN39 A1 F1 CRF37 Unknown Unknown CRF02_AG 
14. SN46 G CRF02_AG G Unknown G CRF02_AG 
15. SN47 D D D Unknown D D 
16. SN50 01_AE CRF02_AG CRF37 Unknown 01AE, G CRF02_AG 
17. SN51 G G CRF13 Unknown G CRF13_cpx 
18. SN52 A1 CRF01_AE CRF22 A1 Unknown CRF01_AE 
19. SN53 G CRF02_AG G Unknown G CRF02_AG 
20. SN54 DH H,B H H H H 
21. SN55 A1G D CRF11 Unknown Unknown CRF11_cpx 







jPHMM COMET SCUEAL REGA RIP Stanford 
22. SN59 01_AE 02_AG Complex Unknown Unknown CRF02_AG 
23. SN61 01_AEG CRF02_AG Complex Unknown G CRF02_AG 
24. SN62 A1F1G F1 CRF37 Unknown G G 
25. SN63 01-AE CRF02_AG G Unknown Unknown CRF02_AG 
26. SN64 A1 F1 AE, F2 
reco 
Unknown Unknown CRF01_AE 
27. SN66 G G CRF13 Unknown G CRF13_cpx 
28. SN67 C C C Unknown C C 
29. SN68 AEF1 CRF02_AG Complex C Unknown CRF02_AG 
30. SN70 C C C C C C 
31. SN71 J J CRF11 J Unknown CRF11_cpx 
32. SN74 01_AE CRF01_AE CRF22 A1 Unknown CRF09_cpx 
33. SN81 01_AE A1 CRF22 A1 Unknown CRF01_AE 








AE /F1 CRF02_AG 
CRF02_A
G Unknown Unknown CRF02_AG 




AE CRF02_AG CPX Unknown Unknown CRF02_AG 
39. SN109 F2 F2 F2 Unknown F2 F 
40. SN111 G G G G G CRF02_2 
41. SN116 A1G CRF02_AG CPX Unknown G CRF02_AG 
42. SN117 A1 CRF02_AG G Unknown A1 CRF02_AG 
43. SN119 C C C C C C 





*Highlighted are examples of different subtypes assigned to the same sequence based on a 





jPHMM COMET SCUEAL REGA RIP Stanford 
44. 
SN120 G C 
CRF01_A
E / G Unknown Unknown CRF02_AG 
45. SN121 C C C C C C 
46. SN124 G CRF02_AG CRF02 Unknown G CRF02_AG 
47. SN129 F1G CRF02_AG Unknown Unknown G CRF02_AG 
48. SN130 A1 A1 CRF22 A(A1) Unknown CRF01_AE 
49. SN131 A1 CRF02_AG G Unknown G CRF02_AG 
50. 
SN132 A1 A1 AE Unknown 
CRF01_
AE K 




AE 01AE AE Unknown 
CRF01_
AE K 
53. SN144 A1 CRF02_AG A4 / G. Unknown G CRF02_AG 




G CRF02_AG CPX Unknown Unknown CRF02_AG 
56. SN148 F1 CRF02_AG A2 / G Unknown Unknown CRF02_AG 
57. SN152 G CRF02_AG G Unknown G CRF02_AG 
58. 






AE CRF02_AG CRF37 Unknown 
CRF01_
AE CRF02_AG 





Table 6.3 RT Fragment for Cohort II 
  HIV Subtypes Using six Online Subtyping Tools 
No. Sample 
ID 
jpHMM COMET SCUEAL REGA RIP Stanford 
1. SN02 G G G Unknown G CRF02_AG 
2. SN03 A1F2 A1F2 AE, F2 A1 F2 F2 
3. SN06 G G A4, G Unknown G CRF02_AG 
4. SN9 G G/02_AG G Unknown G/02-AG CRF02_AG 
5. SN12 A1 A1 CRF22 A(A1) A1 CRF01_AE 
6. SN16 G CRF02_AG G Unknown G G 
7. SN17 A1 A1 A3 A(A1) 01_AE, 
A1 
A 
8. SN18 A1 CRF02_AG Complex Unknown 01AE, G G 
9. SN20 G 02_AG AG G G CRF02_AG 
10. SN22 G 02_AG G Unknown G CRF02_AG 
11. SN26 G 02_AG G G G CRF02_AG 
12. SN29G A1 A1 CRF22 A(A1) A1 A 
13. SN30G G 02_AG A1,G Unknown G CRF02_AG 
14. SN31 G G CRF36 Unknown G CRF02_AG 
15. SN32 G G/02_AG G Unknown G CRF02_AG 
16. SN34 G 02_AG CRF02 Unknown G CRF02_AG 
17. SN35 G 02_AG G Unknown Unknown CRF02_AG 
18. SN36 G G G Unknown G CRF02_AG 
19. SN38G C C C C C C 
20. SN39 G G/02_AG CRF02 G G CRF02_AG 
21. SN41 C C C C C C 
22. SN42 C C C C C C 





        
No. Sample 
ID 
jpHMM COMET SCUEAL REGA RIP Stanford 
23. SN43 A1 A1,02_AG Complex Unknown G CRF02_AG 
24. SN51 B 13-cpx CRF13 Unknown 13-cpx CRF13_cpx 
25. SN52G A1G 02_AG AG Unknown G CRF63_02
A1 
26. SN54 A1 02_AG G Unknown G CRF02_AG 
27. SN55 C 11_cpx CRF11 Unknown 11cpx CRF11_cpx 
28. SN56 A1 A1/26-AU Complex Unknown G A 
29. SN58G A1G 02_AG A,G Unknown G CRF02_AG 
30. SN59 C 13-cpx CRF13 Unknown 13-cpx/H CRF13_cpx 
31. SN63 B 13_cpx CRF13 Unknown H,B,G CRF13_cpx 
32. SN72G C C C C C C 




AE / G CRF02_AG CRF25 Unknown G CRF02_AG 
35. 
SN-105 G G 
CRF02_A
G G G CRF02_AG 




AE / G CRF02_AG 
CRF01_A
E / G Unknown G CRF02_AG 
38. SN119 C C C C C C 
39. SN121 A1 A1 CRF22 A (A1) A1 CRF01_AE 
40. 
SN124 G G 
CRF02_A
G Unknown G CRF02_AG 
41. SN129 A1 / G CRF02_AG A1 / G. Unknown G CRF02_AG 
42. SN130 A1 A1 CRF22 A (A1) A1 CRF01_AE 
43. SN131 G G CRF02_A Unknown G CRF02_AG 







jpHMM COMET SCUEAL REGA RIP Stanford 
44. SN132 A1 A1 CRF22 A(A1) A1 CRF01_AE 
45. 
SN133 G G 
CRF02_A
G G G CRF02_AG 
46. SN139 A1 A1 CRF22 A (A1) A1 CRF01_AE 
47. SN144 G CRF02_AG A4 / G. Unknown G CRF02_AG 
48. SN147 G G G G G G 
49. 
SN157 A1 A1 
CRF01_A
E A (A1) Unknown CRF01_AE 
50. 
SN217 G G 
CRF02_A




CPX G / K Unknown CPX K 
52. SN221 G G G G G G 
53. SN224 BG 02_AG AG Unknown G CRF02_AG 
54. SN232 G G/02_AG G Unknown G CRF02_AG 
55. SN252 A1 A1 A1AE A(A1) Unknown A 
*Highlighted example of sequences with different subtypes as per each subtyping 
program. 
6.3.1 REGA subtyping program 
The REGA subtyping tool characterized 15/59(25.42%) and 23/55(41.81%) of 
sequenced PR and RT samples, respectively. One example of assigned subtype 
based on PR fragment of sample SN52 by this program is shown in Figure 6.4 below. 






Figure 6.4 An example of sample sequence (PR_SN52) of 477 bp in length subtype 
assigned is pure HIV-1 subtype A (A1) colored red in the pol genome. The subtyping 
was performed using REGA online subtyping program. The bootstrap support is 94.0% 
which confirms the sample sequence as closely related to A1 subtype. The HIV-1 gene 
map was based on HXB2 reference.  
6.3.2 jumping profile Hidden Markov Model (jpHMM) 
The jpHMM subtyping tool characterized 100% of the sequenced pol fragments (PR-
59 and RT- 55). An example of subtype inference for patient SN52 based on PR 
fragment is subtyped as A1 as shown in Figure 6.5 below.  






Figure 6.5 An example of sample sequence (PR_SN52) with assigned subtype HIV-
1 subtype A1 (colored red in the pol genome) using jpHMM online subtyping program. 
The HIV-1 gene map was also based on HXB2 reference 
6.3.3 Recombinant Identification Program (RIP) 
The RIP subtyping tool characterized 37/59 (62.71%) for the PR and 26/27 (94.54%) 
for RT fragments. An example of subtype inference for patient SN52 based on PR 
fragment was assigned subtype A1 using and is shown in Figure 6.6 below.  
 






Figure 6.6 Sample PR_SN52 screened rapidly for intersubtype recombination using 
RIP online program. The background contains consensus and subtype reference 
sequences of HIV-1 subtypes with subtype A1 (in red line) being the closest to the 
sample sequence.  
6.3.4 SCUEAL (DataMonkey program) 
The DataMonkey subtyping program characterized all 59 and 55 sample sequences 
for PR and RT fragments, respectively.    
6.3.5 Context-based Modeling for Expeditious Typing (COMET)  
The COMET characterized all 59 and 55 sample sequences for PR and RT, 
respectively.   





6.3.6 Stanford HIV drug database Subtyping program 
All sample sequences that included 59 for PR and 55 RT fragments were assigned 
subtypes accordingly. 
6.3.7 Phylogenetic analysis  
A phylogenetic evaluation for 53 pol RT samples using neighbor-joining tree was 
constructed using MEGA V5 with a 1000 bootstrap replicates (Figure 6.7). Majority of 
the sample sequences clustered with HIV-1 subtype G/CRF02_AG which accounted 
for 58.5% (n = 31/53), CRF22_01A1 10/53 (18.9%), C 4/53(7.5%) F2 2/53 (3.8%) 
CRF11_cpx 3/53 (5.7%) D and other complex forms 1/53(1.9% each). Two of the 
sequenced RT samples could not be assigned to any subtype with confidence. 
 






Figure 6.7. A neighbor-Joining phylogenetic reconstruction of 450 bp pol (RT) 
sequence and a bootstrap of 1000 replications. HIV subtypes are indicated with 
specific colours and include G/CRF02_AG which accounted for 40% (n = 22), 
CRF22_01A1 (10.9%; n = 6), C (1.8%; n = 1), B (1.8%; n = 1), other complex forms – 
37_cpx/11_cpx (3.6%; n = 2). Twenty three samples (41.8%) could not be assigned to 



















































































6.3.8 HIV-1 resistance associated mutations in the pol gene (PR and RT)  
There were no major PIs RAMs detected in all analysed sequences for the PR 
fragment. However, in the RT fragment, three patients had NRTI RAMs and include; 
patient SN35 who had; A62V, K65R and M184V/I mutations, patient SN42 with 
M184V/I mutation while patient SN47 had D67N, K70R, T215F and K219E 
mutations. In the NNRTI category, RAMS were noticed also in three patients 
whereby, patient SN35 had K103N, Y188C and M230L mutations, while patient 
SN47 and SN52 had Y181C and G190R mutation respectively. A summary of level of 
drug resistance for the four patients identified is shown below in Figure8 6.8. 
               Adults: levels of drug resistance against NRTIs and NNRTIs 
 
Figure 6.8 Observed NRTI and NNRTI drug resistance in adults with over 83.0% 
susceptible to commonly used cART. Approximately 4.0% of analysed samples for 
this cohort had intermediate to high level resistance to all classes of drugs available 
while less than 1.0% had Low to potential low level resistance to ABC, AZT and 
FTC. 
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 Overview of Cohort II study  
In this Cohort, HIV-1 diversity and drug resistance analysis were performed on 
73/125 (58.4%) of therapy naïve adult male and female patients. The analyses were 
based on the partial pol gene fragments (PR and RT). In the preliminary HIV 
subtyping, six online subtyping programs that included jpHMM, REGA, COMET, 
SCUEAL, RIP and Stanford were used. The observed subtypes were further 
confirmed using a NJ phylogenetic inference as in cohort I. Genotypic drug RAMs 
were analyzing using Stanford drug resistance data base in the two partial pol gene 
fragments (PR and RT). 
 Observed HIV diversity   
The online subtyping programs clustered the majority of subtypes with similar 
subtypes. The jpHMM, COMET, SCUEAL, RIP and Stanford subtyping programs 
inferred subtypes to more than 90.0% of submitted sample sequences in all the two 
pol gene fragments (PR and RT). However, with REGA subtyping program, less than 
40.0% of submitted sample sequences subtypes could be inferred for subtypes. 
Noticeable difference in subtype inference was observed in two sample sequences of 
patient SN-47 and SN-54. In sample sequence of patient SN-47, a pure subtype D 
was inferred by jpHMM, COMET, SCUEAL and Stanford, while recombinant form BD 
was inferred by RIP and unknown by REGA subtyping program. In patient SN-54, the 
sample sequence was inferred as A1C, C/G and G by jpHMM, RIP and Stanford, 
respectively, while both COMET and Stanford inferred subtype G with RIP subtyping 
tool unable to infer any subtype. Although such small inconsistencies are observed 





due to reasons discussed in chapter 4, majority of these subtyping programs 
provided similar subtypes across all sequences analyzed. A NJ phylogenetic analysis 
was performed to confirm the inferred subtypes by online subtyping programs. The 
results yielded by NJ phylogenetic tree were consistent with the majority of subtypes 
as observed in the online programs. The two samples that had a mixed subtype 
inference - sample sequence of SN-47 and SN-54 were phylogenetically inferred as 
subtype D and CRF02_AG, respectively. Results obtained in this cohort show the 
majority of sample sequences were G/CRF02_AG, accounting for 40% of all 
observed subtypes. The remaining subtypes were distributed among other subtypes 
and complex forms that included CRF22_01A1 (10.9%; n = 6), C (1.8%; n = 1), B 
(1.8%; n = 1), other complex forms – 37_cpx/11_cpx (3.6%; n = 2). Twenty three 
samples (41.8%) could not be assigned to any subtype with confidence. In previous 
studies done in both urban and rural areas of Cameroon, CRF02_AG was 
predominant accounting for more than 40.0% in their study cohorts of therapy naïve 
adult patients (Koizumi et al., 2006; Burda et al., 2010; Hemelaar et al., 2013). The 
findings of this study further reinforce the presence of high diversity and other 
circulating recombinant forms in Cameroon.  Subtype C, F2 and 11_cpx and 13_cpx 
have mostly been observed as rare subtypes in rural areas of Cameroon (Powell et 
al., 2010), but their continued presence raises concern on transmission to other 
urban centres. The low prevalence of these subtypes could be due lack of 
standardised laboratory assays for non-B variants and this means that they would be 
higher in circulation than previously thought. Subtype C causes more than 50.0% of 
all HIV-1 infections globally with countries such as South Africa and India being the 
most affected by this subtype (Goudsmit & Jaap., 1997; Jacobs et al., 2009). The 





presence of these rare subtypes would be evolving, and this might change and lead 
to an outbreak after adapting themselves well in this region.  
 Observed drug resistance associated mutations   
As described earlier in cART management, Cameroon has adopted the 2013 WHO 
guidelines for HIV treatment in adults that include NRTIs – AZT, ABC, 3TC, FTC and 
TDF which and NNRTI that consist of NVP and EFV. The PIs for adults include 
Lopinavir boosted ritonavir or Atazanavir boosted ritonavir are preferred. In this study 
cohort RAMs observed against NRTIs were from three patients that include patient 
SN35 with A62V, K65R and M184V/I mutations, patient SN42 with M184V/I mutation 
while patient SN47 had D67N, K70R, T215F and K219E mutations. The K65R, 
M184V/I, K70R and T215F mutations show intermediate to high level resistance to 
AZT, TDF, ABC, 3TC and FTC drugs while D67N, K219Q/E mutations show low level 
to reduced resistance to AZT and A62V combines with K65R to increase resistance 
to NRTIs. In the NNRTI category, three patients also showed drug resistance 
mutations that were from patient SN35 with K103N, Y188C and M230L mutations, 
while patient SN47 had Y181C mutation and SN52 with G190R mutation. All these 
mutations to NNRTIs had intermediate to high level resistance to NVP and EFV, 
which are routinely used in Cameroon. A previous study conducted in Cameroon on 
drug resistance mutations in adult naïve patients (Ceccarelli et al., 2012; Agyingi et 
al., 2014) show that the K65R, M184V and Y188C were common mutations 
observed. As observed in this study cohort, the majority of patients (more than 
95.0%) were susceptible to the adopted cART in Cameroon, while a small 
percentage of less than 2.5% patients had RAMs. The prevalence of drug resistance 





in therapy naïve adults was 5.4% (3/56) for both NRTIs and NNRTIs. This prevalence 
is low compared to previous studies done in Cameroon on therapy naïve adult 
patients that showed a prevalence of between 4.0% and 8.0% for both NRTI and 
NNRTIs, respectively (Ndembi et al., 2008; Aghokeng et al., 2009; Agyingi et 
al.,2014). Similar studies in Africa on RT drug RAMs in adults show a prevalence of 
1-11% with countries such as Kenya at 7.4% (Onywera et al., 2017), South Africa 
with 3.6% (Hamers et al., 2011) and Mali 11.5% (Derache et al., 2008). Since RT 
fragments could not be obtained for all 125 samples included in the study, the NRTI 
and NNRTI drug resistance would be underestimated or overstated but the results 
are comparable with other study cohorts in Cameroon. The PI mutations were minor 
with no RAMs. 
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 General discussion  
The HIV-1 subtypes and recombinant forms display different phenotypic properties 
that are associated with viral evolution, entry through co-receptor utilization, efficient 
transmission, disease progression, drug resistance and vaccine development 
(Connor et al., 1997; Kiwanuka et al., 2010). This study focussed on HIV diversity 
and drug resistance based on the pol gene fragment in both Cohorts. The pol gene is 
highly polymorphic and characterized with majority of RAMs. The PIs, NRTIs/NNRTIs 
and INIs are designed to target these RAMs during the HIV life cycle. (Vondrasek et 
al., 1997; Gea- Banacloche et al., 2000). One of the major difficulties in managing the 
HIV-1 pandemic is high viral genetic variability. Globally, group M subtype C is the 
most prevalent strain accounting for 50.0% of all HIV infections. This is followed with 
subtype A at 12.3% and B, G, CRF01_AE, and CRF02_AG at 10.2%, 6.3% 4.7% and 
5% respectively (Hemelaar et al., 2011). The CRF02_AG is progressively causing 
more HIV infections in the West and Central Africa region where it accounts for 27.8 
and 3.9% respectively (Taylor et al., 2008). In this study, two groups of HIV were 
identified- group M and group O. In group M, a high degree of viral diversity was 
observed with CRF02_AG accounting for 62.5% and 40.0% for cohort I and cohort II, 
respectively. This confirms the high prevalence of CRF02_AG strain in Cameroon 
which accounts for over 40.0% of HIV infections (Aghokeng et al., 2013). The 
preference towards CXCR4 receptor usage by CRF02_AG is thought to greatly 
contribute to its successful transmission. In a study done in Guinea-Bissau in 2010, it 
showed that the frequency of CXCR4 tropism in therapy naïve patients was at 86.0% 
(Esbjornsson et al., 2010). In another study that was done to evaluate competition 





assays between CCR5 and CXCR4 viruses, it showed that the CXCR4 viruses have 
higher replication kinetics (Tebit et al., 2007). This could possibly explain the high 
frequency of CRF02_AG transmission in countries like Cameroon. More research is 
necessary to understand comprehensively the mechanism behind the CRF02_AG 
and other subtypes’ high frequency transmission. Other HIV group M subtypes 
observed in this study include subtype A at 20.8%, F2 and C subtypes at 8.3% for 
cohort I and CRF22_01A1,B, C, B other complex forms – 37_cpx/11_cpx), at 10.9%, 
1.8%, 1.8% and 3.6% respectively. HIV group O was identified in one child based on 
the IN fragment in Cohort I. HIV group O is thought to have resulted from cross-
species transmission of SIVs that are hosted by lowland gorillas from the West and 
Central Africa region especially in southern Cameroon (D’Arc et al., 2015). It is the 
second prevalent HIV group after group M, accounting for about 1.0% of all HIV 
infections globally. Majority of the group O infections have been observed in 
Cameroon (aVessiere et al., 2010). In another study done in Cameroon, HIV group O 
was found to co-circulate with group M confirming the evolutionary dynamics of the 
HIV (Villabona-Arenas et al., 2015). The prevalence of HIV group O in Cameroon 
would be under estimated due to lack of appropriate diagnostic assays (Aghokeng et 
al., 2009). Likewise, in this study, group O and possibly other new recombinants 
would have been missed in other samples due to the small pol fragment that was 
used for analysis. A full length genome characterization will be necessary for 
complete characterization of the samples. Prevalence rate of RAMs was at 3.7% and 
5.4% for ohort I and Cohort II respectively. Unfortunately, few studies have been 
done on drug resistance, especially on therapy naïve infants/children in resource-
limited countries like Cameroon (Sánchez PR. & Holguín A., 2014). A study 





conducted in Yaoundé, Cameroon between 1996 and 2007 shows an ever increasing 
drug resistance in therapy naïve individuals over time - 1.9%, 4.1% and 12.3% in 
2001, 2002 and 2007 respectively (Aghokeng et al., 2011). In another study done in 
Cameroon in 2011 by Fokam and others, drug resistance in therapy naïve pediatric 
patients was ranging between 4.9% to 8.2% while high levels (9.0%) in patients 
failing first-line cART was observed (Fokam et al., 2011; Ceccarelli et al., 2012). In 
therapy naïve adult patients from Cameroon, previous studies have shown a 
prevalence of between 4.0% and 8.0% for both NRTI and NNRTI RAMs (Ndembi et 
al., 2008; Aghokeng et al., 2009; Agyingi et al., 2014). The high level of RAMs in 
these previous studies would be due to high number of sample size as compared to 
what was analysed in this study. These findings suggest that there is a need to 
standardize resistance testing protocols, especially where there is a high endemic 
genetic diversity of HIV. Thus, infrastructure and access to facilities in rural 
Cameroon needs to be improved. Currently, the FCB is one of the few facilities that 
perform resistance testing in Cameroon. Since the current estimate shows that over a 
million children will require cART by 2020 (Penazzatoet al., 2015), more resistance 
testing facilities are necessary to better manage these patients. The WHO programs 
should be robustly implemented, as they look to support regimens that are more 
simplified, less toxic, have higher genetic barriers and would ultimately require less 
clinical monitoring for each patient, while maintaining therapeutic efficacy.  
 
 







The study limitations included lack of follow-up and treatment and adherence data 
from the mothers. The relatively small sample size of the study cohort which was 
mainly hampered by difficulties in enrollment process, majority of the babies were 
under critical clinical observation with history of severe anaemia. Most caregivers 
also refused to participate in the study. Unsuccessful viral RNA amplification of nearly 
half of the samples further reduced the sample size. The major contributory factor for 
inadequate viral RNA amplification was difficulties in designing the right primers and 
the high cost attached to it. The PR and IN sequences in both cohorts were not long 
enough for a phylogenetic analysis and this was attributed to the difficulties in 
amplifying and sequencing samples with high diversity.  
 Conclusion 
This study provides a summary of circulating HIV-1 group M subtypes plus a rare 
group O that was observed in infants/children. It also provides observed drug 
resistance patterns in the two different cohorts of therapy naïve patients in 
Cameroon. This study reveals that Cameroon might be harboring many HIV-1 types 
and subtypes as observed in both cohorts with the most prevalent HIV-1 clade being 
G/CRF02_AG with over 40.0%. Rare group O and other group M subtypes like 
subtype C were detected even in the small sample size, suggesting the improved 
detection methodologies currently used. This possibly suggests that there could be 
high presence of these assumed rare subtypes if more and reliable assays are 





performed. Subtype C is especially common in South Africa but the detection of this 
subtype in west and central Africa, raises the possibility of transmission that may in 
future lead to an increase in the prevalence of subtype C. HIV diversity has 
implications on diagnostic assays as most assays developed are based only on HIV-
1 subtype B which circulates in N. America & Europe. Further, HIV diversity may 
have implications in transmission, clinical management of the patient and vaccine 
development. Molecular studies in HIV have given an insight into HIV origin, how it 
has evolved over time and its global spread. New HIV infections are being reported 
and may be attributed to the ever evolving HIV. Continuous surveillance of the HIV 
diversity is therefore necessary to better manage the HIV-1 pandemic. Existence of 
drug resistance mutations especially in infants raises grave concerns on the 
availability and effectiveness of the current PMTCT program. The 90-90-90 program 
advocated by various governments and multi-international agencies should be 
strengthened. This will make it easier for newly infected individuals to know their HIV 
status and help to stop further transmission. There is also need to have improved, 
cost effective HIV diagnostic and resistant assays for the region.  
 Future research investigations 
Since the sample size was a major limitation, a larger sample size will give better and 
significant statistical figure that can be used especially in policy formulation. Future 
studies will aim to include more sites in Cameroon for a better view of the prevalence 
in HIV diversity and drug resistance. Future investigations will also seek to sequence 
the whole genome to identify any recombination breaks/events that would have been 
missed due to the small Pol fragment that was analysed in this study. Some studies 





in Cameroon have found recombinants of group M and O which informs the need to 
do a complete sequence analysis for further characterization.  Drug resistance is a 
major challenge to currently used antiretroviral drugs as illustrated in this study by the 
detection of RAMS. Further research will be necessary especially in expectant 
mothers so as to further prevent the transmission of drug-resistant strains to unborn 
babies. This requires continuous analysis of evolving RAMs that could jeopardize the 
successful implementation of cART programs.  
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